var title_f35_39_36464="Kissing bug on hand";
var content_f35_39_36464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Kissing bug (Triatoma) on hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo copyright 2008 by Jerome Goddard, Ph.D.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36464=[""].join("\n");
var outline_f35_39_36464=null;
var title_f35_39_36465="Positional club foot";
var content_f35_39_36465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Positional club foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Geraldo Cabrera-Meza, Baylor College of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36465=[""].join("\n");
var outline_f35_39_36465=null;
var title_f35_39_36466="Contact dermatitis drug";
var content_f35_39_36466=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contact dermatitis due to neomycin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 409px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This contact dermatitis is secondary to neomycin in ear drops.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's photoguide of common skin disorders, 2nd ed., Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36466=[""].join("\n");
var outline_f35_39_36466=null;
var title_f35_39_36467="Pentosan polysulfate sodium: Drug information";
var content_f35_39_36467=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentosan polysulfate sodium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/33/9748?source=see_link\">",
"    see \"Pentosan polysulfate sodium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elmiron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Elmiron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F182912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Urinary",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F182890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Interstitial cystitis:",
"     </b>",
"     Oral: 100 mg 3 times/day taken with water 1 hour before or 2 hours after meals",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients should be evaluated at 3 months and may be continued an additional 3 months if there has been no improvement and if there are no therapy-limiting side effects.",
"     <b>",
"      The risks and benefits of continued use beyond 6 months in patients who have not responded is not yet known",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7272270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F182891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elmiron&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F182872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered with water 1 hour before or 2 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F182871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of bladder pain or discomfort due to interstitial cystitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pentosan may be confused with pentostatin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Elmiron&reg; may be confused with Imuran&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F182910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3%), dizziness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (4%), rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Rectal hemorrhage (6%), diarrhea (4%), nausea (4%), abdominal pain (2%), dyspepsia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function test abnormalities (1%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, amblyopia, anemia, anorexia, colitis, conjunctivitis, constipation, dehydration, depression, diaphoresis, dyspnea, ecchymosis, emotional lability, epistaxis, esophagitis, flatulence, gastritis, gum bleeding, hyperkinesia, increased partial thromboplastin time, insomnia, leukopenia, mouth ulcer, optic neuritis, pharyngitis, photosensitivity, pruritus, PT prolonged, retinal hemorrhage, rhinitis, thrombocytopenia, tinnitus, urticaria, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F182875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pentosan polysulfate sodium, related compounds (LMWHs or heparin), or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F182860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Pentosan polysulfate is a low-molecular weight heparin-like compound with anticoagulant and fibrinolytic effects, therefore, bleeding complications (such as ecchymosis, epistaxis, and gum bleeding) may occur. Patients undergoing invasive procedures or having signs or symptoms of underlying coagulopathies or other increased risk of bleeding (eg, receiving heparin, warfarin, thrombolytics, NSAIDs, or high dose aspirin) should be evaluated prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aneurysm: Carefully evaluate patients with aneurysm before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Carefully evaluate patients with hemophilia and/or thrombocytopenia before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Carefully evaluate patients with gastrointestinal ulcerations, polyps, and/or diverticula before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heparin-induced thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;16 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Pentosan Polysulfate Sodium may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Pentosan Polysulfate Sodium may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F182878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adverse events were noted in animal reproduction studies; however, reversible limb bud abnormalities were noted during",
"     <i>",
"      in vitro",
"     </i>",
"     animal studies. There are no adequate and well-controlled studies in pregnant women. Use with caution and only if clearly needed during pregnancy. Based on limited data, pentosan polysulfate does not appear to cross the placenta.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F182893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9603404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with water 1 hour before or 2 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F182877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Elmiron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $643.24",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F182879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Comfora (IN);",
"     </li>",
"     <li>",
"      Elmiron (AR, AU, HK, KP, PE, TW);",
"     </li>",
"     <li>",
"      Fibrase (IT);",
"     </li>",
"     <li>",
"      Fibrezym (DE);",
"     </li>",
"     <li>",
"      Fibrocid (ES);",
"     </li>",
"     <li>",
"      Fibrocide (PT);",
"     </li>",
"     <li>",
"      Hemoclar (FR);",
"     </li>",
"     <li>",
"      Polyanion (AT);",
"     </li>",
"     <li>",
"      SP54 (HU, MY);",
"     </li>",
"     <li>",
"      Tavan-SP (ZA);",
"     </li>",
"     <li>",
"      Thrombocid (CH, ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F182859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although pentosan polysulfate sodium is a low-molecular weight heparinoid, it is not known whether these properties play a role in its mechanism of action in treating interstitial cystitis; the drug appears to adhere to the bladder wall mucosa where it may act as a buffer to protect the tissues from irritating substances in the urine.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F182874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~6%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and splenic via partial desulfation; partial depolymerization occurs in the renal parenchyma; saturable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 20-27 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2 hours (range: 0.6-120 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (58% to 84%, as unchanged drug); urine (6%, primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Forestier F, Fischer AM, Daffos F, et al, &ldquo;Absence of Transplacental Passage of Pentosan Polysulfate During Mid Trimester of Pregnancy,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 1986, 15;56(3):247-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/39/36467/abstract-text/2436327/pubmed\" id=\"2436327\" target=\"_blank\">",
"        2436327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9755 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36467=[""].join("\n");
var outline_f35_39_36467=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182887\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182888\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182912\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182890\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7272270\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182891\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182870\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182856\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182872\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182871\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182917\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182910\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182875\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182860\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299850\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182865\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182867\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182878\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182893\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9603404\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182877\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182879\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182859\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182874\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9755\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9755|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/33/9748?source=related_link\">",
"      Pentosan polysulfate sodium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_39_36468="Ciprofloxacin (ophthalmic): Patient drug information";
var content_f35_39_36468=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/7/26740?source=see_link\">",
"     see \"Ciprofloxacin (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/50/6947?source=see_link\">",
"     see \"Ciprofloxacin (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9611239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ciloxan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9611240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ciloxan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ciprofloxacin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain in back of the ankle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705389",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye solution:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705387",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye ointment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694922",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gently pull down the lower lid and squeeze in how much the doctor told you to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Release the lower eyelid and keep eyes closed for 1 to 2 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store eye solution at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699253",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect eye solution from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11581 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-424AE69C25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36468=[""].join("\n");
var outline_f35_39_36468=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611240\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030424\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030423\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030428\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030429\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030431\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030426\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030427\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030432\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030433\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/7/26740?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/50/6947?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27971?source=related_link\">",
"      Ciprofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/21/15700?source=related_link\">",
"      Ciprofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/48/38658?source=related_link\">",
"      Ciprofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/5/20570?source=related_link\">",
"      Ciprofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/11/17590?source=related_link\">",
"      Ciprofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/11/44216?source=related_link\">",
"      Ciprofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_39_36469="Ipratropium (oral inhalation): Drug information";
var content_f35_39_36469=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ipratropium (oral inhalation): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/51/39732?source=see_link\">",
"    see \"Ipratropium (oral inhalation): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/59/4021?source=see_link\">",
"    see \"Ipratropium (oral inhalation): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8120000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atrovent&reg; HFA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8120001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atrovent&reg; HFA;",
"     </li>",
"     <li>",
"      Gen-Ipratropium;",
"     </li>",
"     <li>",
"      Mylan-Ipratropium Sterinebs;",
"     </li>",
"     <li>",
"      Novo-Ipramide;",
"     </li>",
"     <li>",
"      Nu-Ipratropium;",
"     </li>",
"     <li>",
"      PMS-Ipratropium;",
"     </li>",
"     <li>",
"      Teva-Ipratropium Sterinebs",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8120010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8120101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma exacerbation, acute (",
"      <i>",
"       NIH Asthma Guidelines, 2007",
"      </i>",
"      ):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nebulization:",
"     </i>",
"     500 mcg every 20 minutes for 3 doses, then as needed.",
"     <b>",
"      Note:",
"     </b>",
"     Should be given in combination with a short-acting beta-adrenergic agonist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler:",
"     </i>",
"     8 inhalations every 20 minutes as needed for up to 3 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Should be given in combination with a short-acting beta-adrenergic agonist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bronchospasm associated with COPD:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nebulization:",
"     </i>",
"     500 mcg (one unit-dose vial) 3-4 times/day with doses 6-8 hours apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler:",
"     </i>",
"     2 inhalations 4 times/day, up to 12 inhalations/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8120100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/59/4021?source=see_link\">",
"      see \"Ipratropium (oral inhalation): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Asthma exacerbation, acute (",
"      <i>",
"       NIH Asthma Guidelines, 2007",
"      </i>",
"      ):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Nebulization:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &le;12 years: 250-500 mcg every 20 minutes for 3 doses, then as needed.",
"     <b>",
"      Note:",
"     </b>",
"     Should be given in combination with a short-acting beta-adrenergic agonist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Metered-dose inhaler:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &le;12 years: 4-8 inhalations every 20 minutes as needed for up to 3 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Should be given in combination with a short-acting beta-adrenergic agonist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8120102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8120136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation, as bromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atrovent&reg; HFA: 17 mcg/actuation (12.9 g) [chlorofluorocarbon free; 200 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization, as bromide: 0.02% [500 mcg/2.5 mL] (25s, 30s, 60s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization, as bromide [preservative free]: 0.02% [500 mcg/2.5 mL] (25s, 30s, 60s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8120003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution for nebulization",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8120124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Avoid spraying into the eyes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Atrovent&reg; HFA: Prior to initial use, prime inhaler by releasing 2 test sprays into the air. If the inhaler has not been used for &gt;3 days, reprime.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8120060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Compatible for 1 hour when mixed with albuterol in a nebulizer.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8120017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticholinergic bronchodilator used in bronchospasm associated with COPD, bronchitis, and emphysema",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8117604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Atrovent&reg; may be confused with Alupent, Serevent&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ipratropium may be confused with tiotropium",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8120049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Respiratory: Bronchitis (10% to 23%), COPD exacerbation (8% to 23%), sinusitis (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6% to 7%), dizziness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (1% to 5%), nausea (4%), xerostomia (2% to 4%), taste perversion (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (2% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (2% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (7% to 8%), cough (&gt;3%), rhinitis (&gt;3%), upper respiratory infection (&gt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (4% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening):  Accommodation disorder, anaphylactic reaction, angioedema, bronchospasm, corneal edema, eye pain (acute), glaucoma, hypersensitivity reactions, hypotension, intraocular pressure increased, laryngospasm, palpitations, stomatitis, tachycardia, urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8120045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ipratropium, atropine (and its derivatives), or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8120046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/bladder neck obstruction: Use with caution in patients with prostatic hyperplasia or bladder neck obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Inhalation/nebulizer not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. Should only be used in acute exacerbations of asthma in conjunction with short-acting beta-adrenergic agonists for acute episodes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8120053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: Ipratropium (Oral Inhalation) may enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8120042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8120043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Inhaled ipratropium is recommended for use as additional therapy for pregnant women with severe asthma exacerbations.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8120044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8120138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Atrovent HFA Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     17 mcg/ACT (12.9 g): $258.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ipratropium Bromide Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.02% (2.5 mL): $1.76",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aeron (AU);",
"     </li>",
"     <li>",
"      Aerotrop (AR);",
"     </li>",
"     <li>",
"      Aerovent (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Alovent (VE);",
"     </li>",
"     <li>",
"      Apovent (IL);",
"     </li>",
"     <li>",
"      Aproven (AU);",
"     </li>",
"     <li>",
"      Atem (AE, BH, CY, EG, IQ, IR, IT, JO, KW, LB, LY, OM, PK, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Atrovent (AR, AT, AU, BD, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DK, DO, EC, EE, FI, FR, GB, GR, GT, HK, HN, ID, IE, JP, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, PY, RU, SE, SG, SK, SV, TR, TW, UY);",
"     </li>",
"     <li>",
"      Atrovent Aerosol (NZ);",
"     </li>",
"     <li>",
"      Atrovent N (SG);",
"     </li>",
"     <li>",
"      Atrovent Nasal (NZ);",
"     </li>",
"     <li>",
"      Atrovent UDV (KP);",
"     </li>",
"     <li>",
"      I-Patrimol (PE);",
"     </li>",
"     <li>",
"      Ipratec (PK);",
"     </li>",
"     <li>",
"      Ipravent (IN);",
"     </li>",
"     <li>",
"      Ipraxa (NO);",
"     </li>",
"     <li>",
"      Optra (PK);",
"     </li>",
"     <li>",
"      Rinatec (GB, IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8120084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks the action of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation; local application to nasal mucosa inhibits serous and seromucous gland secretions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8120086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Bronchodilation: Within 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 15% of dose reaches lower airways",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein Binding: &le;9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henry RI, Hiller EG, Milner AD, et al, &ldquo;Nebulized Ipratropium Bromide and Sodium Cromoglycate in the First 2 Years of Life,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1984, 59(1):54-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/39/36469/abstract-text/6230059/pubmed\" id=\"6230059\" target=\"_blank\">",
"        6230059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes DT, &ldquo;The Use of Anticholinergic Drugs in Nocturnal Asthma,&rdquo;",
"      <i>",
"       Postgrad Med J",
"      </i>",
"      , 1987, 63(Suppl 1):47-51.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mann NP and Hiller RG, &ldquo;Ipratropium Bromide in Children With Asthma,&rdquo;",
"      <i>",
"       Thorax",
"      </i>",
"      , 1982, 37(1):72-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/39/36469/abstract-text/6461943/pubmed\" id=\"6461943\" target=\"_blank\">",
"        6461943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmond MH and Klassen TP, &ldquo;Efficacy of Ipratropium Bromide in Acute Childhood Asthma: A Meta-Analysis,&rdquo;",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 1995, 2(7):651-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/39/36469/abstract-text/8521214/pubmed\" id=\"8521214\" target=\"_blank\">",
"        8521214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuh S, Johnson DW, Canny G, et al, &ldquo;Efficacy of Adding Nebulized Ipratropium Bromide to Nebulized Albuterol Therapy in Acute Bronchiolitis,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 90(6):920-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/39/36469/abstract-text/1437435/pubmed\" id=\"1437435\" target=\"_blank\">",
"        1437435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilkie RA and Bryan MH, &ldquo;Effect of Bronchodilators on Airway Resistance in Ventilator-dependent Neonates With Chronic Lung Disease,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1987, 111(2):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/39/36469/abstract-text/2956405/pubmed\" id=\"2956405\" target=\"_blank\">",
"        2956405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9148 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36469=[""].join("\n");
var outline_f35_39_36469=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120000\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120001\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120010\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120101\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120100\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120102\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160029\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160030\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120136\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120003\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120124\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120060\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120017\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8117604\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120049\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120045\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120046\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299541\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120053\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120042\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120043\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120044\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120138\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961981\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120084\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120086\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9148\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9148|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/7/21620?source=related_link\">",
"      Ipratropium (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/62/13284?source=related_link\">",
"      Ipratropium (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/45/19155?source=related_link\">",
"      Ipratropium (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/51/39732?source=related_link\">",
"      Ipratropium (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/59/4021?source=related_link\">",
"      Ipratropium (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_39_36470="Micronodules PA";
var content_f35_39_36470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Micronodular pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Standard International Labor Office film for small rounded opacities, less than 1.5 mm in diameter (micronodules).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WRGdgqKWY9ABk1N9juiMi2m/79mtHwggk8Q2qMMg7+2f4Gr0WLSYnOWj2/7tAHlQsLwni1uD/wBsz/hTxpl+elldH6RN/hXrqaRsHyYKj161cgWFQN0G4jrmgDxgaRqR6afeHnH+pbr+VP8A7D1b/oF33/gO/wDhXucUlssbhrNtpGCQ3H5VqRwWUqFYnaNs5UScc/WgD54/sTVc4/sy+/8AAd/8KU6FqwGTpd+B727/AOFfSR0vI6DnuvehLAINpAKn9KAPmj+ytR5/0C7/AO/Lf4UHS9QAybG7A/64t/hX0hc6Al0DJGAjd2xxVCXRVizGV57+poA+ezp16Bk2dyB/1yb/AApPsF3/AM+s/wD37Ney63pP2VwhXIblT6isv7GT1/AUAeX/ANn3v/Ppcf8Afpv8KUabfHpZXJ/7ZN/hXqK2pA5FWbe0JbOOKAPKU0bU3OE069Y+0DH+lWE8M68/3dE1RvpaSH+le46JYNnODn3ru7G2EEOCcsefp7UAfKw8KeIj00DVj/25yf4U/wD4RDxL/wBC7rH/AIBS/wDxNfWkK4OcZz2q6g3KCcLx0oA+Px4O8THp4d1n/wAAZf8A4mlHg3xOTx4c1r/wBl/+Jr7Ejz0HKj25qaJ8HnBoA+Nf+EM8Uf8AQt61/wCAEv8A8TUZ8J+Ih10DVx9bOT/4mvttVEiEAAjHFZU6gMRtAI/WgD47Hg/xMwyPDuskeosZf/iaevgvxSwyvhrWyPawl/8Aia+woZAhWPHDD5s1a09iwZQO+RQB8aHwV4qHXwzrf/gBL/8AE0w+DvEykA+HdZBPTNjLz/47X25IgZQqniqskOwgkL9KAPi3/hDvE+P+Rc1n/wAAZf8A4mkPhDxKBk+HtYA/68pf/ia+yLh+CD9Oec1kXt3FFnzCAfVj/SgD5MPhPxEOugauP+3OT/Co28M68v3tE1QfW0k/wr6dm8QWUbbS25fUdqhuNRtpNuWADdCD1oA+Y20LV0OH0u/U+ht3H9KjfSdRTG/T7tc+sLD+lfS1zaQXceEdQ/UCsa400q2yRAy+hHBFAHgH9mX/APz5XX/fpv8ACnJpGpOQE0+8YnoBCx/pXtz6Gd2+2BKk8x9T/wDXrqPD/h3aFeWM+aentQB85J4Z16THl6Jqbf7tpIf6VJ/wifiPn/iQavx/05yf/E19c2enJbAtgbyO3arDWgZlbbnaOKAPj/8A4RLxISAPD+r5/wCvKT/4mmy+FfEMQzLoOrIPVrOQf0r64uZfsa4AZnx1x0qg101yAt3Ekq54HTFAHyrB4W8QXDlLfQtVlcDJVLORjj14FSL4P8TMMr4d1kj2sZf/AImvqu1smhlM2nMA5XaUkQNwevXiuq1CWR5TdpqE5jknc+RHGqnZk4CtjgjjJPXtigD4pg8I+JLguIPD+sS7Dh9llI20++F4pZvCHiWCIyTeHtYjjBxueylAz9StfZ89lbxx6W91CkdsrN56xS/e3YIJGc54JNZOtCM+UuqXDXN7kmUo4ZMZXaWx1AXcNoweetAHx4dB1gZzpWoDHX/Rn/wpg0TVSMjTL4j/AK93/wAK+0Tt+12JjzIwD+UhmXKxlT9xhwi5/hbcfes3XLNmvWkaeWSZlG8SMrsuBgAuoCnjB4Ax0oA+PX0rUEzvsLtcesLD+lQSW08SlpIZUUd2QgV9Yy2TEMSeOua4b4p2+PBGpPk4Hl7R7eatAHgNFFFAHSfDuPzvGOnp6+Z/6Laval04AjaPrXjvwrXf490tcZ/1vH/bJ6+jI7FXILYDdCR3oA5xLHDYA6npVk6ZHIMMNrdjjmt42SAgsT9c1NHAgx8nPqTQBz0ejyE4IXy+mSOtWZNJMa7shh39q6a2hLkgqauxWAYZAwPSgDjbYTW7AQZxnBXqK3bOAXce4oqTDorcA1YNmkMjBYwSD1I4/wDr1BNFIxBZjkdPQUAWDbNFhFIwOvHWoLixWZcgfN6+lXbOQsm2Uc+verqwjqvbvQBxOq6WtxEIpR8wOQ2OlctLpjRSMsgww9uor1q5slmTGAGHesq+0pZl2uBvHRhQB5nJaYbhc+1aunaVkgzKQMdBXQf2K1tLmVMv1GemPWrlvY8EkZA5JoAZp1sNwCrhF56dK10VAeSM+9Z0l0kETGNwoH8WOvsDWW+qhA7qThc856mgDqN8YO1QS3t2p0U0ZYKXz656muDPiCRlKsxJJz/k0lpqMrvxIyEdCDQB6RDJET8sgz71aiwW5AOK4y0v5H/1h+Y98frW7YXhyMtkD17UAdNGAUwoAGKybsFJG6cdzVy3nV/uNx6VBeRiRhuJBzxmgDJuJgjli+09Kv6NJvY4/MnrSf2ZHLE7biSDkAVY0qBY5gMnHXFAGjGM/NyM+tRzhlZmLZJPp0H0q8UVQOBgnpWRqcz7mWIDGKAMHWL8W4ZYz8/Tce30ritXleQNvcjPU1v6vhXYE5bHJNc3qDK0R3naPrigDm7h9jleOnPOc1LbSRSIUYEFRlee3pVS6uIA2AS3PYdKqC8SKRT5ZJB596ANe3vHifAldMHoeQa6fS7lrh0hkCvuHy4Oea5SG2W5kXeHiUnO4jP6V2Gh2cUaEWjoWz8zvwQKAOk03RwriTGXJ4PpXQxWQRSVUbu+Kg0aYIio3I7v2rcRNwyD16Z5oAy1hLHJ6VFOc5WPOO9aF0hC/LnGecVRKYJz/wDroAy5IDzgkYJOTyOabsIGWwQPmAArSaLntz7VXkiw5HbvQBACee2egzV+zmbZtLZz2NVAgKgjB+lSxZUDqaALhtYbhiNvlufQZFUbjRlR8h1x14qXzGX7rYx6HFSQ3h4Rzx+hoAoLYJEuERcE56daFt88Dj9MVrbQy7o8jjoaIERsAgfhQBg3UYJ8sgY/rXB/GC32fD3VnHT90fp++SvTZrf524zXDfGqLZ8MdYyOgh/9HR0AfLFFFFAHY/CElfiJpJHUeb/6KevpqCE+WGyrf7oxXzP8HRu+I+kAjOfO/wDRL19T2Ee1yp6YoAbHCWHIytPjsIg2FZs/3cVbCnOB29KmO2FcnOP50AECRwrhucdhTxKvQdaqM5c5J47ClGSMGgB0mXbOcj0qvJEO469qse3GKcRk8kDvQBTSLY2QADnPSr1u42jd+NIsR6v19MYAqVVxjB5oAlEYYArjpxT1thIu4rz2NSRJ5qmNuBjGRwavbQFwOAP0oAx57JCMSgFR61yXiK4mijCWyMYj36fn6V2Gp3iAbAA3b/PrXGatFNK+8vuiP5D8KAOXvLgZVJZ1OOoXnFZeq3sUUARVdi3PJwMVtalZxv8APEvXn5elc1q9jOWjOOOmc0AUkvixIWMAdsGtCyuozywZSfTtVC3sgHHmOQDxhRmta3gjUARAYzzjmgDcsJXIBiKuB1Of0rorSbG1ZVKk8DPpWBZx4hyoBYnqOK07WZlJVju46Hk470AdPp+BJwcH/PNXb4sr7QNwPcGqFhho9y9Mc1cvG+bOPlx0oAfDJiJDjox71ctEAn3IOo71jRXBztKfKeRzWxprlicrjAoA05CAuPTpWTqH3G2nHJwa03ztGRyRnOKzL5SNx2nBORkUAcRrSybmyAAe5rg9aWbfh2LBugBr0nWISWZm4zx7VxOtqpQmMANjr3PNAHIvauQeM+1OitHAG6InBFaFrbzzN+4QsDx9K6DS9PEThpP3kg5A7LQAlhYSSiMyIyR4HJHJ+ldBaxlE8uJdqqMBcdT70xEkZy218Zx7flV6BjF13ZxzkUATWc7R9GIJ4Nb1hrMciiCUAr6j2rirrVI3LRoen3jjtT7OVWK+U2PY80AemxMsiBlIZD3/AMahmtjklFyuM89qxNKvJIyGDHn8q6WGRLiPMeQw5wKAKAhPTHfNV54MtkrWwY88jg+mMZFQTRAngZoAx9mACFLZPbtS7Nwznr6CrkkQC9MVEq89OMUAVnjz6Z6dKieI55z+FXmiJ+62OCBkZwe1DxewzQBXsGKOEclk9T2rRaAoxOODgj2ql5fPI/CtSzIlgKNyydD6igChJH8zHnB5rgPjguPhfrfBH+o/9Hx16W8ODkYDCvPfjrGF+FWuY4x5H/o+OgD5HooooA7f4LjPxL0YDP8Ay26f9cXr6rtRnnGMCvlT4LqH+JejqwyrecCPbyZK+srWMBQMdB0oAsRooO8n5VFU3JlfP8PUe1Xbk7Ylj6FvmYe1VgoPPpQAwJzTlQge3Ye9SDAZVyQzZwPUgZI/KpQvNAEJjwRjn3qVI+cj86cV59v51PDHz/Q0ACRAZ6YHPNSJFuPPTuasKmegH49qmCD6IOf/ANdAEIXy1+bgf54rPvdRChgx2jtipb653sypkBcDpj8R61zuoyKo+Z9xJzz2oAfKxmJIHXnNVTGA4yQefwrOnvWt3zIwRD0Hcj2FEGqxSY8kblz1c8j8KAH6jaLPzHmNhyeMggGsHVNOdIW80qADkEc1vTztNHy5I/SspPNSSbzWVkLfu154XAGDkdcgnv1oA5TYqkszx+yrn+dPjQMQqsP5VtXOnW8pO2FgWOSVqB9IEWGWQkgd15oAltDLGArAYxzg1tWabzkAegBrDhtJQcrKpA7EGtjTwyyAZGR6HNAHSWCGMoUJVTxitueIMc4XOM9KzbDnuTjv0rckXIXaAAVA/GgDPjhjZuIxnFalhCiZUDt0qO2hG4tgkDqa0IIgjH2FAD3UFVxge1Zd1HuYkjJ962wuBzyKoX+2O3aVRwB+RoA4PXoWaUruAQVyt3BaRgBmLMedp71v6vNJPLIBkg85PpWBcQSk5C5B4z3zQBQeUghIVEQ9B3q7ZRPIrFmOcUQ2Bd/3sqqF9OTV0tbwx7Vd/MYZ6c4oAhkcQwl3ZgE53g1l3GpyzBjFK6KOgB60y/ZZlffK+OgAXjNZM3lrGQs5zjuuKAJRqtwr4Lh+edwBrSstViZgHRo/9qPkfiDXLCJmbETqTmpovMiOCN3uDnFAHqWj3ZkTMcglHqDgj6iun067w4wwB9q8n0S4KpvV+p4IbvXZ6VqZIAnG7H8Q+9/9egD0eF1mj3KRn0oZN4OQc1i6deEFXRt6e3UV0KlZF3oRyOaAM6ZMrxggVVKBF6cj1rVlh2s7bnO85wx4XjoPQd/rmqUkZBYZ5IoApJIzJ8y7G7jOR+dSMuevJHfNPC4OMGhVAAB6epoAj2gMTn61LaEpOrZ9vwoKgfxZb3owcDjnPSgDQaNXXHGR2rzr4+QlfhLrxxgfuP8A0fHXorHKbhz/AFrz34+N/wAWi14HnHkc5/6eI6APjmiiigDufgiM/E/RR/12/wDRMlfW9qoUZOCe1fJPwRO34oaKf+u3/omSvraBicfXrQBHMd8zEjpxzQAc0KN0jHOcmpVX86AEVBuG4AnqD/WplXpTVwOxNS7QR74oAZGhLe3rVy3jI649qiiQ5wetXogPwFAD0XAx05yeKgvZBGu0dTzVossaBnPJ6D19awNQugpZpD16L3P/ANagCvdzcMdwVB3Ncvrt7sA+zjGT989RVnUrsuecnsB2/CsPUVeSAsQVA5560AYt3MWdiSS5OTzmobZ5EkMisV460tzKEG6NfmPHvVCS5ZTmVhGncMeaAOrsr6IoI5uWxkGr6yI2DGF254K1wa6rDG67d7+hzgVftdVcyfu0CY9KAOpumIjIwS1UQZDIpBJUjGc9KpxazJI5E+GUg5I4Iqa0voXcRuQsg/v8D8KANi2jDKuMD1q5aWolmCgd/SqyzKZcknJ/KtbTw27dgD3oA0bOJw3A+QdO5FbzJ90DAwMc+tZNipaRSN2Djt0rphGp5I7UAU7bKFlbAyOtX4Bvc9gB1pqwo5HAq9axhSdq4FAELZC49B1rG1HOJIyNquMj610sydQOD3rn9VQoWbr60AcDfWzK7bh8oPeqNyqCEvIRGq9Sa09WkjXdJI4CjsfSuN1fVopyURjhTwP8aAK093NdTNEgZUxjHdh70jTJHwGzjg85P41SMrp8wI3EHp/jVETgkqOHP8VAFnUJoEO1pHRiT2rAmuYlmG6ViOm0r1q3qCsVMzyREJww6H2rmp5/Ml3Ae2TQBrLcRPyJ0X0UnBFXrTeei7we681yruGJOfpmr9i8kW1kdlf2OMUAd1amJ4lDYGOp6HNbFiWDZjkJ46E81x9nqbblW4QTDjkcEfjXTabPCy5gcmT/AJ5scN/9egDqLC7aOcbXII9a7bQtQWQbScHuOxrzyzmV+GU++/qK6HTmaMhlJPt3oA7/AGgrg8elUZlK/KeMHrmpNPuRNCAfv49afIBKN6diR3GcUAZ7rhs9D3pMY4/LmrEg4Py8+9IqBiGoAg2HI9PTNIyjvU5ADKHwMnA560koHT0oAniJaIbutee/H0H/AIVFr3XgW/X/AK+I69Btxlcdf61wPx/z/wAKi1/j/n3/APSiOgD42ooooA7n4Jf8lP0X/tt/6Jkr63g4XkV8k/BH/kp+i/8Abb/0RJX1tF8qE4ycYyKAGRgH2z1qyF9elQxDBz/I1MDz6UAPCnB2gE9gTgVLtx/+qmoRuHY1Ix5/DtQA+BTnHGzrnvmr0a5HAAHSq0IzgDI96tM2yMtjGBQBV1O4EMWc8emeprir+V5JWK/MxOSTyK6LU5DLXOXQ3ZEeMdz6fWgChcSLFz95z39Kxb25hjINxIckfcHJP19Kn1HUBHmKAlnzzMf6Dt9a5W/lKMe79cGgCvqt48chEGyOJumOv4k1z8gkMrNkuf7xOc1qTbpRgjC9OazLmAwsCkhPoM0AQpPmPIHzdcH1rU0+4WRMbhuPTJrOjkRs74xkn0q/Zv8AZyjRqODngDmgDZjI83YiljwMim36MWOM47g9vf6Gte2nMtus0a7hkdKbbS7ZSJcSbicAjOKAF0a8aNAsr5HRQf4a6uzuZETKMWJ9axFS2KpiAZB4YHBxXR2ESSKvlkBscCgDpNGZnRRnD59OK6sHhcDqMEiuT0ZT5yqQQK6tMZUH8xQBLCmCPU9quwryOPrUNuvTODiriLg9cf1oAbIMZ6VzuvAmN8cnHSunccHIzWTqFoJSQV4IzyKAPF9ZjSSYpJk4OOtYN1pMW0yAM5/iUnAA/wA969O8SaGU3T2/DAfMuP5H1rjLiTykyF3NnBB/rQBzF5aPI3ysqIq4VBzj3zWJd2hjUSSSADB6Dp+tdhKYJ45XTMTgfMOxrjdddvmSNgBnkCgCjLbNcP5jS4jKYBY4rn2tykzh3DRj7oC4I/HPNblxxZwqTltx4B7VSaINJkspLDOM0AV7e1UgyOzY/hq0kRLARuc+460jPltqMvHHBFTW6jaG3KAD8xzQBatleEgldx9ewrSjnBwoOT7GqULvHMW+8D3XpWhAqScyIFY85HFAHR6RqTbhHODKox8x+8v49/xrr9OlztkjfzI84yO31rgbOEI37jLdiTxxXRaXcNC6lCdx4I7fjQB6Pp83KN0NdCCGjBXof0NcVp9xvxtABHYH+Vdbpc3nQlCfmAyKAEmUbs8nJxx2qAYVzntWg6HocZNUnXmgCI7UOVUbsYLHr9M9cUwnnj8afjnA/Co3HTHfvQBNb/UHiuE/aBK/8Ki10Ac4t/8A0ojruovvYPSuF/aB5+EevEdP3H/pRHQB8bUUUUAdz8Ef+SoaL9Zv/RL19aZIQjHOK+S/gj/yU/RcjPM3/ol6+sycJ9KAJIsHIHb2qVQcnOagiJHJOasxt6DBNAEobH4nBqVASwz19ai2g4zx68dangXJ7UAWYuAKZfOFUKSOmcZqeNct0461n30m522n260AZl2PlYbz1J+Y/dH4dq4/Wrv70cZwnf1b/wCtXQ390pBijPB+8fWuWvIQWYzAbsnv1/GgDnrwPIxwSB3Y1UcRiPrvfH3n4/Kr90WchFBJ/uKO1YV/LFbvukYu4/gU5x9TQBXunG0hmyeoxWe5JyW6eppLvUDKCAiIAeq9RWdMWcBtxbPWgC40kYIAdcdhU8N1Ggyylm/z2rHdXVucgYzSwNhh060Addpt6u9znYGB4Hf61v20AuAkqyqueOTzXFWU5WZSpK5BBHqKvLM0XypIY03ZABxQB2Em6E7CFUg8EHmt3RJTtBJ5rzuPWLlW2yBXx/F0NdX4c1ZZFzOpUjgY7UAer6M3mGM4HTmujt0Fc14XZXiDhtwI4NdXGRtBx+J70ATQxgMasKCeajiAAA6/jmphyefyoAHHHt61WmAx157VayMAAc1BJyOv60AYGox7kIwD+FeR+MJIbC9kRyMN8wxXrmryfI/JC9OK8D+ILifWZArZCrjA+tAGXJqZMm3BVHzjPPPauXuw+8g/NnnNXPm3HERJ6gHtT5rKRirqgKkE5z0oAzWX92ynICjtWY+AWPbFdHdQmFZEBRhjGeTzWTLYSALvkQMTnbjrQBmbRgk4HoO9CscDPQdBVia3YOQj7vU9BTGgCYaV93+yKALFndywMGjchu3cVv2N8shH2tcZ/jT/AANc4gO/iMgfmRV23l2t1IY9Ce1AHd2eDCWgAlQc7h2HuK2tMIZl8zjb0I6ivPtPuGjdTDJIr9mHHNdxpF0ksQS5KRXH94DAb2PpQB1NmXiZSDx/errdHu8tEVB64YelcjZsykLIMH0Irb09/LuEdW+XvQB2zqGy+T0qtKmH9R161PayBo0II6UTqQ/HQ0AZknDZ6CkKgYz0qxKnyk+npUJwwoAavXjGa4P4/kn4R69k/wDPA/X/AEiOu99s1wXx+/5JFruf+nfH/gRHQB8cUUUUAdz8Es/8LP0XHX99/wCiZK+r0J59PcV8n/BTj4m6L/22/wDRL19Wox2jIANAE6YyCcY6ZFWo+gH5VWj5PFWkXA7+tAEqkkgDoatwjHfntVaEfMMmrluu4njGBnntQBMSEj5POM4rA1CUqNijJPWty6fbCfTHSucvCAXY4LE/lQBk3X7vJBG4j8vpWFqbK0BeZlRB09T9BWvfOiLvcZx91fX/AOtXKajO8km+XDdhjsKAMXU795f3cY8lDyQp5b6mucvNpTamQ688963NRgyCyfLg5Hc1lXVjMcPIuMjjB/lQBhzEKcqcj6U1RIVDLnHXJrRnSKMZMYyeCD3qtKS6DA7cDHSgBhdZwscx2lRjI5qeGGIqE3AHPDY61R+YNyOfpR5m3ncAD1FAGxFCIpULjPPr0rRC27NyNqg8k84NZWmyRPE5Y7XTpjpVyKRxfOpXcrjAHX8aALz2OVDKAeST2FdJokKAKNhOcE471lQhksCrAlutdJ4btxPHHhsEdPrQB6R4ZT7PZr/DurrYeQCB161z1lEUWJOCVHODW/aglRkAUAXocAY9T1NTg4NQQjI5GCPWph90etADxyfSoZgQD6U9QQOc+/HWmyjsf50Ac14hPl2UrAjcRgE14JrKO95cSNuLjPIGc817v4rJ+zkA4rxTUQ0MtxCcEdQxHSgDk1IllIkO0AEnPFSM5jQKpYhMnIHYVBerErgpIZGc9BxUeoef5IIIIxg7c+lAEaTloJCFAVjgt3P0rMnkCE4cswzj1qO9dorFEjOATg1j72Zm5I7CgC27ux29CKbjnJY5HtzVMuyjAY+3vUizsMFsM30oA1IDsyzHr0APWrqBZHyygn1/pWPBNtOZACc9BWxp5jkYGSQxkcjI4/SgC7b2537ouV6BTW3p8gBCyghhzj1qnbgLwGBGf9ZjIrTgjQBfNdG75oA6XSdQKqI52yvRWPVa63TGI29CDyPeuAtomwDHhkBznOSPrXW6Dc5URMSFyACetAHoGlONqr6+/StGQFo+eo55/lWJp0hWRRnGCM5rcdgGxnOaAKrrkY9etVWXaxHWrsi4yAM1VlTLDpQBHjAHPB6V598fgR8I9eB/6d//AEojr0PaOffsOteefH85+Emu5GP9R/6PjoA+OaKKKAO4+Cn/ACU3Rv8Att/6Jkr6sj7cYr5S+Cxx8TNGP/Xb/wBEvX1ZG/zYGaALUXNW0PA659qqRgAknvjqeB9Ktx8EENn69qALUSjgsOhyMjvVqAEL06mq8Y46GrcQOcDg9aAIbp8ZyfwrnNQdUR3bgLW5dOHY45965bW5NzHbyoPIPrQBzepXJZyz5AP6VhyiVgSrDBPXsK2ZrffkyEgdl71QmSTIREYduRkke1AGcCY8hckngnHNZtzE6ghehOQSelaF88cBIMnmzDqqnhfrXP312875Y5UdAeBQBXnnhHErBnz1UVnlwXzGu0Hjceanl2zHLLtPqBVW8iMYG3LAjpQBDc2k6vgsCOzA8GqrwSYIwSRVtZpFj8vG4ZyBmpYXckMVVRnoelACaZZXMwPlqdijrjNanl+SIHyQxAySD71uaFJdRELEU8sLkAAZx71JPCt67uGwQPuE/rigCO3kndcI6t6gc5rvvCFsojgaVCrDn5q4C0gKgiIEn1BxXo/hkSi2j8xjyAAGoA7ewYs249e1dHa/w9T7YrlrFjgFDkeldLatlVHXjrQBprjA96fwBn371DF15BIx39am4YEH8hQADr2xUcxAB7cd6exI9MD9KgudwTv+VAHM+JmTyjuUe1eSa9btNMdqAgnnd0xXrusx+bgZGD+lcVq2n7y4jIU/T7xoA8uvNP2zllUYHIOOKq3VnMohZR1PIx613i2Um8JIAy54yvSnPpOZChj+VTgjtQB49q9ssTyhmZSD8qkfmc1iFVIxH0z+de3eIbWyns/skQgaRAQdyc/XpXll3pbxTMsJVlzjAB4oAxPIyBjG7rzTysajC/MehJ6Z9qum0MIx8rN/EQc1W8h25I+X0WgB9uEQBup9u1XEmwxOzO5cHPpVREI+ZkwB2qYAgAHJJ5FAGvptysGdnKkZIPT8q6KxuLW6bZEvly4/1bE4+oP9K5YQtCirMCHI3YA59q0tO2+ao2Fs9SxxQB2enNJAQu0EfSul0yMbvMVcEc4HrXKaVf8AmKqXGAvQOOCvsfaut0sNAqg9xkHqCKAOo0yXfjBIK9feuqiYvbqc4rjrT5WDpn3FdXYPui+negBzg9/zqvIvY45q5IMc44PSq8g9QPb1oAqE7e+K88+P5P8AwqbXc4/5YD/yYjr0NyVOOP8AGvO/j9/ySbXsf9MP/SiOgD47ooooA7b4Mf8AJStH/wC23/ol6+qoMbhnGcYzXyn8Gzj4kaP/ANtv/RL19U25wc9aANGM89OPX0q5BxgYxVGMkkAmtGAAYDA8+1AFqPGQAOAKsqdqEnjAPU1XiU59ulWJceUxB9KAMe/cqrdieAfSufmQqv7xixx1/rW1d/MxLZIHAHr71h6is0kUqwOqTYO1mG5FPbI70AZNypLEBQTnIPT8a57VLoYeO3ZyxHL+v0rZvbh5IFindc4wzrkAn19h7VzuoKoUlSAgH3h3oAwJl2H5mP8AM1TuHQYwfmB44zzV+VGdwEUgnPPXNVXs3bLECNfQ8k0AUWdpMqBtPrnFMa3kCDYCQc5Y9KvLboq4OM55yMn8qXcPlK5JXt70AZbWh9SDnqKmjskR/myQeR2wa0rVj5nzp8p5J9DWhFGs0m+VFEQ7k9aAH6LELVIzkANyynv9TWzFMJ5RiNFQc8LWJdyQbgkUqnb1X/69bfh795buj7SAQyMOcA9jQBq6ZaRM+/CqxPIA611mm27L95eh7Vz+mweY6+Uw2g8ketdrpEO6Ib8Zz3oAvWURD5I69RXQWkeMe1ULe3fCbNp5wc+ntWzAgA/woAlXO0AYzU2cA5pkfRc5qVRwSBxQAxhkdx/SorpSYjwM1Pgc0ki7lIoA5TUd3nDoQe2KyruyEq71HzD2rptRiAIKjHpWS4KklsrjqfWgDkruP/SEGzJJ5I4qy6xKAWT3b3FRazexwy5TGScZPbFVJLvzIwSFHNAHNeK4WDCWCMrI4PA7/hXJRW1zJGPtMZjkXIIxjI967TV4ZbuZJUBKqfvk4Uf59K5zVdRea58qCRSFJVpCPvkcflmgDm7nTU83cCoBPK5ziqc1uI3I+9j24q/d3lwlywmWNlXjGMiqctwowsq7foeTQAwDc4VIwcn+7k1IlqivnIjl9+g/Cn2uppGxWFgDj+7zTo5Y5nDsmcnj5v60AVnt50kLySeYufvZzVu1Dl8DBPfuAKuxzICFWGPaB7nFWliinclUEWepTjPtQBd0yIkq7YCg8DPJ/wDrV2Gk3WT5cmNh6YP3a5CK3EY+Q5UnqecVrWJ8vb8xJ9e1AHeWTlHUdq6rSOI+uVI4GelcRpU4lUAZ3KK7DSW5GSRnrQBsSYKfSq7jIGP0qdlzuzjPTPWqzEorZ5x6DNAFOcBSc9M5rzX4+Pn4U66Ov+oP/keOvTLtiVZexryz47n/AItbrg/64f8Ao+OgD5HooooA7L4QHHxF0g5xzLz/ANsnr6ot3BUeg6g18q/CRtvxC0kj1l/9FPX1DavgDGKANq2OT1HpWrAPQ9fasm07VqwtkcYoAuwYwWGDS3BHkNg89c0lvjH170t4G8lSABjJ569uKAMK6GTWBqc7fMoVSPWty7dYoztGMcAAdK5e8YENIVJx1oAybjO7kEZ6Lmsy5j8xmd23Adug+lbFyvmjLn5McjoTWTdM7SfIPlXhVX9KAMuddr7lPbqBWdM2SN/T2NaF7IsWS3bjaDWJfXDSZyQgHYdaAElZVbdkBh1APNQmcBJNgSMjncTkk+lUmb5WznPr/Sq/mHdnGeeaALwnmwZCzMh4z0Gas2Fz8xjcZWTg9yDWbJdySRbBxGvSMDpT7Jym5kJIx1PUUAaEkIDlWzkH6g10/hASfMqk47etYOhSvcyNHcp5iAckjqa9M8O2cEdis8aZ3ccjp2oAu2FqjM8qsqHjccdDXW6MX8kBvmGT0rAgSO3SRlIAxzWvoby+VgHPoG/xoA6uzYEhfQetake0g4wcHB+tZdgJMDeqhfUH9a04N5HzIB75zQBOo9BzTpPMELGBEeTIwHYge5P0pEJ47nsamXvQA04yQMYzxSEfIeKcSegJpG4HQ4+tAGbfIGHTk9xWFqKMiMR87fyrorpSSeOSePpWVdQkpkZyOtAHBa9bMtm8rRkcZU9g3vXMabJcXEZEqS4yOdpORXourWjvC6oM7uqnkGuYt92lu6xgqzcYYZAHpQBT1B4rWxKzuh3dAcde1ee/aITO5AVsE52jr612uvvHdAq+FGPvAc15xqVm1tfu3GCMlh0+tADbvzZlby0AY5we9YE0UqErcZ3ds1qx3kqlo1c89/Ws+acicI6kKT1I60AUWkKkqgx6kU+3dlfKkCpZkg83puB6EH+dKIzGwLKCDngD+dAGtp98wUiRdyH7x7/nXRWsYlZTbyAr1Cgc/SuQidz8oJA9PSr1tcfZpAUfc69weBQB2lp8shDKNmcEEZFX4oiMmJSFU8g9fw9axLDWVuSou1RD/wA9VGB+NdDaDa/RueeDxQBq6QxV1JyO+TXcafIfLDKCfYVxUKoXDRj94BkjFdTo83Kx57DigDrW/wBWrDHI71Wl5Jwc5/wqeP8A1QyG4/Ko5BjFAFGdQc569K8u+PYx8L9d69IP/R8derS4wcmvLv2gFH/CrNbI/wCmH/o+OgD4/ooooA6v4WEDx5peemZP/RT19O2rD5PWvmD4Ynb450s+hk/9FtX01YuWCEdKAOls+i8VqwKMZI596ybMnaM56VrW+SBxyaANGAHKqTzin3eCuOOODjnH1pIVw446Cn3f3CeDgZoA5TVW+YrnAHFc88WwAFiyjjLHJ61016q4LZ+b2rDlGWPA4BOT296AMSaPMjbMknJYngY9TWFqmojLJbMABwWArR1y6Z0aOMZhPfP3v/rVxV7IcnBwQw6dKAIrmTIJOWJ71lTBh6Yz61akuCi4bac8jA61CIWuE+Rck9PpQBDiQxN1J7VAY5GXAXIPHPArUttOLZ86URj0HJPtTktYemXOP73AoAzI4GVwFBLd62LGwLh1lRlI5yDjNWYljEfICntnrU4ZyqKgGCeDjmgDU0SyjRFdlCE8ggEiu+hgktLeNAGwRkH198YrC0C0ZbVFZXcgZYdq6C5kmZrdQoVVXnf3+lAFW7ul2rEVySfmJziuv8Ko8kZMiYOOlc9Bpy3EolwTjGB/Wuz8OxeWpUnPOOe1AG3bqcdOnar0YOB2/CoYkI/wqwq5xzk0ASKMZ/wqVTxTFHINSDnpkelACYPPHBpSDj5vT8KXGQfSlHTJzn0oApzjGB+NVjDnORwavSgHleAahC45OBQBl3FrySoGK5bX9N3fvFGGHOa7eRcFuv5daydRjR1PB3H9aAPHtQhJYxs2STyCw4NYWuWKNZnaUHZuxNdt4zsFtoGvFjm3KcnAAIFYOmix1DSZd7MZguDuHJH1oA8+XTIZJ9nnbe+Se9M1HSCkgEk6s7n5AeMjtW9d6WVut1v84XOSfSs0zbVMM0eY8kdct+dAGALF7cM8sahfrmonkJBxIOe2OlacrvG3ls27+6o7Cq91bAxBgoJbr6/WgCCJ0aPAkBbHOBU0KCPrjgdM9aoMvlZZfnx6danhuN/3Rtz04zmgDVtJAWDEAD+VdfoV75aKkpLxY4PQoa421kVpQcgHuBxXR6buABwvB6qOaAPQbIkEFnGwc7sjBFbtr8squv44rl9DuSIxHLgIeh/u109ouJVBBAoA7S2bdAjAnHWiXOcN1/SodM+a0IIBAP6VPKMp+PIzQBTlFeXftAf8kr13PrBj/v8Ax16nNyMdPwryz9oHP/Cq9cyO8HP/AG3joA+PqKKKAOn+Gv8AyO2m/WT/ANFtX0npLksi559K+bPhp/yO2m/9tP8A0W1fR+nHE0ZB70AdlY52LxWzbjgc/mKxtPOVHHPr0rbthkUAaMK9AM0zUCPIIPQ9alhHA646nmoNWbYFHqOfWgDnLhX8zgcmuf1t1MbJE3A6jP3j/hXQ37iJCc/Me57CuH1WfY7Z24x2PFAGBqbMpYlwvXjrXP3UsMjAmMtkZ+U4rdvoTPuKZyVyR61nLbxxfdA8wfw9t3rQBkrbxMN7B44x/e5P5Ug8tU/d7mX16VbkI3t5xTYeu0VRlMat+6Y7T1OOKAHFwWDH5MHnuKnimSaQKHAbu7DArMndNoXeB6kHrUSReYcmXKj88UAbPnWqtl5d46ExDr+NdLp0sSRK6IIoh/ERuP8A+uuJt4YwigF1JOOB1rqvtMTLBboWXGAFHc/TtQB0NnfvJchYGbYOcd2+tbuC1uJA7OR/tdBXLaTG0U8oU5AXHynAJ9K3JbkxW8cYIJC5JoAvQ6i8BEZcuF5AB/Su48OXcssYd8cDp0rzeO6Fw0NrDCic7mY/e/PtXofh9xGEAXgevWgDsoTuQGrKc9RVW1YMgJGKtR8Hk5yaAJQOeOfenj8DikHXOPenD1OKADPbv/KlAx70c8dz6Uv160AQSD5RUG3HNWpR0OMfSoG6n060AQN94Z/TmqNzbhxgjA9K0COcgEc1Ex2EjHPrQBz+oWKXELxSxhkYd6801LRX0ia4aFMQucbs8AHtivYblmyFCIc9icVg6vbi5gnhKqydOR1oA8O1AGIkxHL45xx+lYV8QjCT5cjqR6+ldJ4mtbnRbxzJCJbRidki8bT6GuNu5Ek+dGyHHIB6GgBt1dQSRAEDzAenc1XSUPGWVeB1XBJFVvMXcFkiJwf73SlKFgwgc/NwQev0oAmcMHDbFIPI96XykmfcdsR9VPT8KhtpSXaC4cYJ69atx26JJhW8wjv0zQA8xtAMqC3o/Y1uaTKVCmRQQR1PBzVS0QSsyhWAPVSeGA/rWlFYlSXjDYGOO9AHRafdbyNwBPTpXZ6TcedEOcsOh9q8/tJtjLj5D3x3rpdCuyJxgnjrx1/GgD1DQ3LQuD0HTmr7AbGBxxWRoTgE474ArXfg4OR3xQBTmHy4647V5V+0F/ySvXOnWD/0fHXqs2cE9a8q/aDx/wAKs1zkdYP/AEfHQB8e0UUUAdP8NOPG2m/WT/0W1fR1hkOvNfOPw0/5HbTfrJ/6Lavo+xXGznOPSgDrdPPyAnJzgcDP410VoOK52wPCnp7CugtDgcnmgDVhGQv061V1fnaxPAHWrduePWsvxA5S0ZhjduzkntQByOr3e+Qjdx+lc7eK0pIJG3rkVqXK+czbjgZ5NZsuIxiRv3YOOKAMGYlY8R5BJJ561nzxtMrDhW9uv/162NRRF3SB9ynoucE1zd3dNA7SJLiReAq9B/jQBnTgJG8kjqi54BHJrNnu2ddiSbV7gDGakvZZLlvnHsDj86qCEhgXzg8YoASOISuBvySeauxWhVC0mAnQY5pIBGqGTYdoyMZxSNO0hxjCDoM0ALukZtsO70rotAdbT99JmSYnByO9YqTtGoK8A9gK2tEtHnuVeT5U7lhwKAN+0uWnvMRDagXJGMc1swxbztZRhh1qjYQ28CkxYdS2N3pWs8bm5hCsSijOPagC1pGmKL9pcjYfau70qDBBydvpisDREZo0WMfLnOK7PT4Nh5PP8qANS1UCPnrV1V6DjnkVWgXCjAH4DFXEzwOmaAHKDnnPXsaeM/TFJz+PrTh6UAAo9KMfSlA9qAI5eozjGRioCPTPHU1Zf7tRFTyOc/XrQBAy446ZqGSPngdatlTkcYHvTCuDnqMUAUZYw2ARgiqEiEucqvz9q1ghKYc5OOo4z+FVngBY9sUAef8AivR4bmKRmjDQupDrjOD64r571rTLjRr10fLKSSknZh6V9Y3lpuLjg4BGD3zXmPjbw0t5azROu3+JSR37YoA8M3pOpVwPNXjOaghkaGfa5/8Ar1PfWUlldyQyod6k9ehFVirZEe7PHDZ4oAfOr28+5BkZyrAdvSr9k5aQN90AgtuqKzuJQVikVWVeu4dPcVLht3yuQrHmgDagOWDR52k54PWuh0qYR4LgsewzXF6dctDNsfcFPGK6KxmRxtV8ODwCelAG+6qVzAg3HmtPTZcIgIbjpng1kWG9XwwIJPBI5+tasMLGTegH+1jvQB6R4bnDWa72AO7HNdLMcAE4/OuN8NSBI0jIyrDBB9K68cqoA7YoAqzdD15/SvK/2gefhXrZHT9x/wCj469SnO1m9TXlv7QJ/wCLV63zn/Uf+j46APj2iiigDp/hp/yO2m/WT/0W1fSViOE5xXzb8NTjxtpp95P/AEW1fSFgWON2AvG3B5989qAOsshhQa3rdsJ1J79KwbLO0YBz7VuWnOAQOT+BoA2ISfMT7uzHPXOf8Kx9ZfeXUMMDitYsEjZueBgcdKxLw7twHJoA5W/AhkVE285IB6n1wPasa+kVVDSnc5/hFdFqYijj3yqpkAIQ4GR689QK4fUJ23ySSbsqMAds0AZeo3zJKVypGOcc5rDmCEM5UKueCO9Xr4ltzN8oA59axLnzJCGAwPSgB7urqFjQbyc7vQVFGEXJdOSeveliVIk3sCW7DPFRgtKy8nB74/lQBMQjIpUfKGxipo7VGTcY2RScAnmn2cO6QhF3KM9a3YLULbxvKdpLY45oAz7KxXzV2k7P4ie1bLFIT5YLZY4K+tBhReC6rH6kdfwqWC6t4kEyRlpz92RyOB6igC7b27Iu1m2qCPbHtXTR7DhlYtgD2BGP51yBkefflmDOclj3Fb1gx+xg7iTjAoA7HSrkCVI44x5aj6YrrbKUOFyAR15PSuH0eV0jRXwTjuOa7DS8MV2g8HvQB0MZyBn9KtJzyQTj061Uh6Z61bi4oAmHJzSgU3B6Dg/TNOHB9hQAv4Ud6MUtACHGPrxUbHk+tSHAHJ/WotwYnaCffPFACHjAFMY/Lgj6088k8Zx6Ux+OMAY7UARjAPyjBqFkBPGKm4BJznNRSDDAgYOe1AFK6izjrmsfULYyxuo79Qe9bs2QM5JzWddfeBHagDxTx74TW58+W3/dzLyo7N7V5isLBAvkBWU9Vr6X121SaMuQMj0rxvxZpptLsyx5AmJDegP/ANegDkZIPOhIRP369WHeqVszRExtzg556g1ovEdxeJsOB93PBqncQh5iSmDjODxigCSWQxnc/wAyN0OKu2xA2ypls84BrPhnjKASxludpG7FXIGWKIsgI+YEHrigDsNMuQ6qJNyseOTnFdLpimR1z06DtxXBafNuceW2w/xD1ru9JuP3CgcEj5SR2HagDrNOyjLtOFHT2rsraUSwIwIPHNcRYSAQAk/e+7XU6NIfKeI87ADxQBPdnDMOQDzXlfx/P/Fq9cBPP7j/ANHx16jeH5cn3HNeU/Hw/wDFrtbHB/1H/o+OgD5EooooA6X4cnb40049OX/9FtX0lpz/ACKfwr5o8Ats8W6ex7F//QGr6L0qZvLywXbxg9/xoA7XTjkAgfSt6yxvU+grmtKdXQFSCD3rpdPwSe3Hc0AaEsm21we9Yd3IoO9mOzbk5rVunBjCr78VyuuXJ8sKOVU4/H1oAytXuC8pYYweB3ArkNWIkkBU7SOntW1eXiujKWy4GOKwp3Vz9zOOQD2/GgDBuwxBQj5gck561RdBu5BVPcV0dxBHKmQRnoQOufb2qrNEIYiZVAkJyny9qAMaa1aQggEIvCgjr70+K3IbghiavSRu8W05AHzEnjFQyyhFUptOF7cYoAtF4bSJUXPmZwT1FWjeiGBVDJvXk57CsG03TTrucHJzuJ4FSX8u27IjKkg59etAFu4vXnbc5Ij9OhY1JDMrcMxLYwF7Zqgoluh8uflGCAO1XLOH5iZEdgD2GM0Ab1i7NAQ2DsGV/wAK29PZ1jQu5CYyQBWJYxlpFjgiIDkcH+Gt6dHjuo4IjuSPG70+n+fWgDrtNRZgssXyocY9RXW6amEB5JPrWD4cgHkqCvB5we1dPawkHB4xQBqQZKjJq+gwF449qpwIEwB6dKtxrhmPPzds0ASL7Y+lOHYUncd6UdRQAvWl9aTNKKABv8mozUhyBTMHINADM9c9qY44PHtUoH5Z5pH9cCgCA9CRnOKibGQSMGp2wBzj3qLA9SfegCvKDtP8qzbkAhiykDHTPNakobBxjNU54ywLAc0AYF2waJlABGOjV5v4qtlkSSOVTh/ukjpXpd9HkNgHIrjtWhW6do5MZP8AF/WgDxW5BtZ5EZc84PHXFWI4ElQBlG3qAD8wNT+JIJLS+Vjkrkq3HX3qhBMcBkZtwPAI/WgCLULCRULwp5gDcHHf3pmjq0Q+z3BMhd9zsegJ7D2HtW/bTG6gAcbSvBI4p4063WISiTy25O0jJb6UANtrf7K4G7LDoa2LK4ZLhWRiVJ6nIrCMu1lDcpnAPcVbhnRXVN+ex55FAHo9heLcqpB6cEe9dTpFz/pZB/jXFeYaNfmK4XngDkeo/wAa7TQ7o/bl9+5/nQB1d0f3cm3C856d68o+PT5+GWsjt+5/9HpXqkx3Bh6juK8m+O7Y+GusKc5Jh/8AR0dAHyhRRRQBu+CTjxPYn3f/ANAavoPSmDRL0/OvnfwiceIrQ+m7/wBANe+6M+Yo8cCgD0DTXyikkfhXT2BCwO3t3rktKY4QCumEgS2VFGTnB9qAC/nCQEE/fXGM9q46/l3xtGhHIwPb2rR8QagqzLhiQo2jP65rj9Ru2MrAEkeo45oAp3Uo3EbskdcHFU5JSVK5UORhcf4VFdMFJlODngE/570+1hkuG2QRPNck9V5x7UAPRMFeQHGC3oPX8fepZWDKC4w3QEnqP6V0Wk+FriX5tRkESDHyrz+ZrpbPw7Z28h8uBd2MFm5JoA8qOnahekLaW08qnqdu0fiTVu18FahI2yZkiy2TtyxJr2azsFTI2Dn25GPQ1bt9OQAnaMj17UAeYaX4ItYOZg8kinvwD+VasPg+zjcv5A3t1JFd+ttHH8pG4nv2FKLUGUxFSMY2v6+1AHFReHIU+7Gox0OKvf2BCefLXfjpjr712P2EY4XnI+UdqfHahQGlKovAyT+lAHJWfh1Y13hFyegI+7T10RT8569OetdmlvuztJwenFItnk9OvegChp8CxKgUY7c1vQqCAT07VQMSQnLttXOBn1rQhwFwORQBaRRwKtp09/5VVQ5x296sIM4IPH86AHjkdc04deOlIODjrQM57Y9qAHdvalPXn+dIKUdMCgBD+tNPuadimtwKAGkgn/61L3OfyqJjnn8qTdjIoAVxkjk4HYd6iYc/060pYYwajYgg0ARyHnpx37Yqo7ZOQePWrMp3DgZPvWfdNtYgjJPpQBSvkBDYOAw6k1xOpQssrvkcdRng12l2FkRlP159a5jU4C0m73zzQB594qsDLbyBF+ZhkHHQiuEtbd0nKyoxYcE+let3cYljKSHnqpHavPdfhW21B8EYbkKDjmgCqkyxSNnkggfL0Iq8pHmAqS2R0z0rBmuFUMVCkZOcnkcVDHqAA/dtls9Qe9AG5f5ADR4808FcYB+vv71QjuEQ8Aoyj7pPSlt78FPLm5yMgZ6GqN2okYNC2T39/wD69AG9b6gREGLAE9RjtXZ+DtS82UKSN0Y4yc5FeWR3QXGGG31963/Dupm1uVcEZzg+470Ae+wy+amSevBryf46n/i3usj0MX/o5K9F0i4ErBVztddw5rzf47N/xQOsDH8UX/o5KAPlqiiigDX8KHHiC0Pu3/oJr3XRn+ROegrwfwyca5an3b/0E17bojKUTIyMcj1oA9L0JtxQ9cDNbuoT+XaFtwyBgc+tc94dJ8kspUD7p4OfwqbxLd+XGIsnjnI7UAc/4hvAWReo2muUvLoEgKwL55I9ava7c7kV0J5O0Y+8a0vCmgGMrd3aBpP4UPIX/wCvQAuh+H5dQVZLsbExwnfH9K7rTNKhs0EcUSxx9MKOvvViziEacKWAGSF6n6VrW8KvhkI2thsgfeFACRw7UVTx9aswwhR82SexApkU0LXptfmaReuOinrWokPI4oAbBGBnOMn17VYVMZHYdzT4o8Hlh6fjVmJAePyyaAKjWkZDr5XMgOc9CenNSwRp1K4bGBx2qwgSSJipV1IIORwQMg5/WpbUpJFHJH8yOoKnBGR2680ANWLOM/lT2jU8EA/UfrUuML93npgUpXk7sEDoPSgCILuI4G31z1poXPUEHnvVgjPJ6dKXbzQBVaHcOQD655zUkaZ68ip9nFAQjHHGOaABBtzjg+9WF4AGc47k81Go5+lSjrkUALnBxinD86QUv4HNAC+9Ln0pPxwOvNKOmRigBDj86idc9alzikJ56UAVz19c9MUwqxAwD68VZbBGCOvb1pCTj2NAFZoyBycAfjQsSnqxIqxyOoGaZzjLEAevtQBEbaNjk89+tMe0hb7yZ/GrCg5LHAz0HpRgAHofrQBnPptocfuunuarTaRYOTm2U/Uk/wBa2GXnkEn+dNZMgkcUAYB0exQgrZw5B4ytZuraHp8mWaxgZhyD5Y4NdW6k9eT0qGeJSmMDNAHll14c0uaRt9lEN3/TMAVi3XgrRZCxFqiv6qSK9LubIB328Cs24smOXA+tAHj2p/D7JL2NxIMnoecVhaj4d1LTYy0kXmJjlk7Ad8da9xNowbdjA9D0qO4hWVCsqg574oA+bbnCkvGMr/Fjp9al02dpLmJg2cEAe1eo+LPBkF2jzWiCK5I4YDr9a8wi0+fTNUW3uIyjA8elAHtnhK+MnlDOTG2PwNc18e+PBGrDJ5MR/wDIqUeC7sx6xHC5xvBXH8qT47nzPh5qEn+3Gv8A5FSgD5cooooA0vDxxrNsfc/+gmvZdCl/dqQcivF9DONUgPuf5GvXdBfdHgjnGeaAPVtAYiCFORuXf+Oaw/FF+G1O9UE4RgOvQDitjRQubcgkbQPx46V5zqN9JLrVwFIZppGULnuTxQB0vhnTjqlyZ5FBjiPyA9zXodnaxhAqKuxRgewHasnwtZfZbGKIKTtGWIxyf0rqrdEjxtXGT2U0AS2kJUAdMetaEafK+GK8HBAzioIgu/GV9cE81dh4PGce9AEOm232dJ2lBYs+8MwG7PfnvyTWtEoz71V2q/lhyCynII4Gf89qvoFwCCDxjg54oAWEKxAxh8dMfyqXy8PuH3T8p4oQqGVc8nkD1qdAv3Tn+dAD1XPOMe1PA5OaRRz708DAxigBAMdOQKXbgnjqaXHp/OnYwenFACBcgdPrQAOemfSnLg5AzQB3PGP0oAFBzRjp/Klxz2x2zSj1/H6UAJt9+fapBz6VHGiooRFwo6DtUgGeTn6mgBR1PIwPSl+gpBx1I/Cl+hoAOMY6+oNKPfFICO3b0paAF7YpmOT2+lO5/wAikzknnpQAgGP/AK9IMsoLKVPoSDj8RSsQAR1+vemFjjPWgByqAXwWOTnBPA+lIyDOdufTnpSKxLELjH1qQcev0oAYVwO2aY/HU9KlI45OaYRlfegBhyPp9KafvH1p3PakyoYLuUNg4GaAIXDNIoAdVHzF1YYJ5G0jqRzn8uaZKBtPGRjGasHI64qJ/mTjOOnSgDKkiA4A+UDAqq0JYnIP41qyLtBLAn6daikXj0IFAGLPCrjBGPYcYrKmgMb7hnA710UqjeRzn6VRnjyCDyKAMN4g/Xn271yPi7wzHqVq8kSgXEeWRh612s0flNlRgd+KYYw6EHOOmaAPBdGvWtNWjlmJVo2AbPYg966X4zsH+G2r8E/6hwT/ANdU/wAay/iVpTaXqv2qNQIrg4OP71Xfi4/mfCy7kAPz29sTn/rpHQB8z0UUUAXNIONRh+p/ka9V8PSfKvJ9DXk1jIsN1G7nCr1P4V2+k+ItOt1Aludvf7jH+lAHvGmyhIgx4AQY/KvPdCtWvPE4YDcY3LDHr2/rVq1+InhtLRFfUiH2gEeRL/8AE1B4V8beFNPmnnutUCySMcf6PKePXhaAPbNLj2RIBj1JxWxGOcj6c15fa/FnwXGBu1oA/wDXrP8A/EVfi+MPgdf+Y7j/ALdJ/wD4igD0tFIX5Aue2RxVmCNCdyqATxnvivM0+MngQYZtfIPTi0n/AD/1dTp8Z/AKgD+3hjPIFncD/wBp0AeoRYwAzOe5BORVpA20dz2BHH515cnxr+HoIJ1/n1Flcf8AxurEfxw+HYPPiE4HpZXH/wAboA9Py3JVY8++akRiTggE9evSvMF+Ofw7CADxDnAxzY3H/wAbqQfHT4c4wfEXB6j7Dc//ABugD1JW4p4IOK8tX46/Dgf8zFj/ALcrn/43Sr8d/hz1/wCEj69f9Buf/jdAHqgxjHWlAB5wK8sHx4+HGP8AkYvzsbn/AON07/hfPw3/AOhjP/gDc/8AxugD1E+oJ47Cg9MivLv+F8/Dft4jx/243P8A8bpsXx6+HDJufxAY25BX7Fcn15/1f+c/hQB6ljPelwQDzzXl/wDwvr4b5/5GPp/043P/AMbpf+F8/DYAf8VH/wCSNz/8boA9QViMbsA/Wn5zzjmvLB8evhtnP/CRken+g3P/AMbp3/C+/htj/kYx/wCANz/8boA9Txn396d0PSvLB8fPhtnnxJ/5I3P/AMbpR8fPhr/0Mn/kjc//ABugD1LnHH60jAl0bceM5AJwfqO9eX/8L9+Gv/Qyf+SFz/8AG6P+F+/DXP8AyMn/AJIXP/xugD1Ln1xQ3XmvLf8Ahfvw1wf+Kk/8kbn/AON0x/j58N8HHiQ5P/Tjc/8AxugD1I845oIH4+prytfj38N8c+JP/JG5/wDjdOHx8+G3/Qyf+SNz/wDG6APTwMHNSfQYNeXf8L8+GvGfEmfX/Qbn/wCN0D4+fDUf8zJ/5I3P/wAboA9RA444NNIODgYavMD8fPhr/wBDJx/143P/AMbpv/C/PhtjnxHz3xY3P/xugD02RRICjYxxkA/lSnDHI/OvLJfjv8NSHK+IVDkdRYXIJOOMny+aVfj18OMAt4jG7HJFjc9f+/dAHqPrUbjBztya8x/4Xz8N/wDoYiP+3G5/+N0n/C+fhx1/4SM5H/Tjc/8AxugD0pxznoarSryB09PevO5Pjv8ADg9PEWff7Dc//G6rT/HL4duQB4hHHf7Dccf+Q6APQpMMDg5qpIvBBHNcE/xu+HjD/kP8/wDXlcf/ABuqh+NXgPB/4qLfx3srjP57P6UAdxcxgsRVKTKk5OSK4uT4z+BWB/4nuD/16XHP/jlULn4veCXI2a4SB/06TjP/AI5QBueNtLi1jRpInI3qNyt6GuD+LCtF8KJ0Y5ZYLdD9RKlar/FfwVIrK+sZUjBBtZjn/wAcriPif468Oa14PvtP0rUvPuJBGETyJFziRWPLKB0BoA8MooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36470=[""].join("\n");
var outline_f35_39_36470=null;
var title_f35_39_36471="Subclavian steal syndrome";
var content_f35_39_36471=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subclavian steal syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/39/36471/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/39/36471/contributors\">",
"     Peter C Spittell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/39/36471/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/39/36471/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/39/36471/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/39/36471/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/39/36471/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/39/36471/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"subclavian steal\" refers to a phenomenon of flow reversal in the vertebral artery ipsilateral to a hemodynamically significant stenosis or occlusion of the subclavian artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In most cases, subclavian steal is asymptomatic, does not warrant invasive evaluation or treatment, and represents an appropriate physiological response to proximal arterial disease. Subclavian steal syndrome implies the presence of significant symptoms due to arterial insufficiency in the brain (ie, vertebrobasilar insufficiency) or upper extremity which are supplied by the subclavian artery.",
"   </p>",
"   <p>",
"    The physiology, diagnosis, and treatment of subclavian steal will be reviewed here. General considerations for patients with symptoms of vertebrobasilar ischemia are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39273?source=see_link\">",
"     \"Posterior circulation cerebrovascular syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclavian artery occlusion or a hemodynamically significant stenosis proximal to the origin of the vertebral artery results in lower pressure in the distal subclavian artery. As a result, blood flows from the contralateral vertebral artery to the basilar artery, and may flow in a retrograde direction down the ipsilateral vertebral artery, away from the brainstem (",
"    <a class=\"graphic graphic_figure graphicRef62622 \" href=\"mobipreview.htm?31/29/32210\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Reversed vertebral artery flow, although it may have deleterious neurologic effects, serves as an important collateral artery for the arm in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Coronary-subclavian steal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A coronary-subclavian steal phenomenon has been described in patients who have undergone prior coronary artery bypass surgery (CABG) utilizing the internal mammary artery (IMA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In the presence of a hemodynamically significant subclavian artery stenosis proximal to the origin of the ipsilateral IMA, flow through the internal mammary artery may reverse and \"steal\" flow from the coronary circulation during upper extremity exercise (",
"    <a class=\"graphic graphic_figure graphicRef76733 \" href=\"mobipreview.htm?39/22/40288\">",
"     figure 2",
"    </a>",
"    ). Coronary and graft angiography demonstrate retrograde flow in the involved IMA during selective catheterization of the grafted coronary artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/8\">",
"     8",
"    </a>",
"    ]. Simultaneous coronary and cerebrovascular ischemia have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Identification of a significant subclavian artery stenosis prior to CABG can prevent this important problem. Those patients with a high-grade subclavian artery stenosis should be treated (percutaneously or surgically) prior to CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerosis is the most common cause of subclavian steal syndrome which is more common on the left side, possibly due to a more acute origin of the left subclavian artery, resulting in accelerated atherosclerosis from increased turbulence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of conditions other than atherosclerosis can cause hemodynamically significant subclavian artery stenosis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Takayasu arteritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=see_link\">",
"       \"Clinical features and diagnosis of Takayasu arteritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Compression of the subclavian artery in the thoracic outlet (",
"      <a class=\"graphic graphic_figure graphicRef59433 \" href=\"mobipreview.htm?17/58/18338\">",
"       figure 3",
"      </a>",
"      ). The site of arterial compression in thoracic outlet syndrome is most often distal to the origin of the vertebral artery. Therefore, the potential for symptomatic steal is low. However, these patients can have posterior circulation strokes due to retrograde propagation of thrombus. Athletes, such as baseball pitchers, cricket bowlers, and golfers are the most likely to be affected due to compression and subsequent kinking of the subclavian artery as it goes over the first rib.",
"     </li>",
"     <li>",
"      Following surgical repair of coarctation of the aorta [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Following surgical repair of tetralogy of Fallot with a Blalock-Taussig anastomosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28794?source=see_link\">",
"       \"Overview of the management of tetralogy of Fallot\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital abnormalities such as right aortic arch with isolation of the left subclavian artery and anomalies of the brachiocephalic arteries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/15-18\">",
"       15-18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27735?source=see_link\">",
"       \"Vascular rings\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of the subclavian steal phenomenon appears to be much higher than the clinical syndrome. In the majority of patients, the finding of \"angiographic steal\" appears to be clinically insignificant and is not associated with an increased risk of vertebrobasilar ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/19\">",
"     19",
"    </a>",
"    ]. In many patients, subclavian artery occlusive disease is found incidentally by noting a blood pressure discrepancy between arm pressures or on ultrasound testing of patients with carotid or coronary artery disease. A careful history and physical examination can identify patients at high risk for developing this syndrome.",
"   </p>",
"   <p>",
"    Whether the steal phenomenon is the principal cause of cerebral ischemic symptoms remains controversial. This is based upon a number of observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reestablishment of antegrade blood flow may not relieve symptoms",
"     </li>",
"     <li>",
"      Exercise rarely provokes cerebral symptoms",
"     </li>",
"     <li>",
"      Occlusive arterial disease in the other extracranial arteries is often present and may be a confounding source of symptoms",
"     </li>",
"     <li>",
"      Retrograde flow in the vertebral arteries is commonly identified with duplex ultrasound and is often not associated with neurologic symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with subclavian artery stenosis are asymptomatic. When symptoms occur, they are most often due to arm ischemia, but this is uncommon as well. In one prospective study, 500 patients with asymptomatic neck bruits were followed over a four year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/21\">",
"     21",
"    </a>",
"    ]. Of these patients, 9 percent had severe subclavian stenosis and over half of these patients (64 percent) had a steal phenomenon. None of the patients had symptoms as a result of arm exercise. Reversed flow down one vertebral artery is usually asymptomatic or causes, at most, vertebrobasilar transient ischemic attacks.",
"   </p>",
"   <p>",
"    However, symptoms of vertebrobasilar ischemia are also uncommon and tend to develop only when there are concurrent cerebrovascular lesions. As an example, anomalies of the circle of Willis, the most important collateral route in the cerebrovascular circulation, occur with increased frequency in patients with symptomatic subclavian steal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms, when they occur, are due mainly to ischemia of the ipsilateral upper extremity. Exercise-induced arm pain, fatigue, coolness, paresthesias, or numbness occur in approximately one-third of patients, but ischemic and trophic changes are rare.",
"   </p>",
"   <p>",
"    Less often, neurologic symptoms can be caused by vertebrobasilar ischemia of the brainstem. Symptoms and signs of vertebrobasilar ischemia may include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dizziness",
"     </li>",
"     <li>",
"      Vertigo",
"     </li>",
"     <li>",
"      Ataxia",
"     </li>",
"     <li>",
"      Dysequilibrium",
"     </li>",
"     <li>",
"      \"Drop attacks\"",
"     </li>",
"     <li>",
"      Diplopia",
"     </li>",
"     <li>",
"      Nystagmus",
"     </li>",
"     <li>",
"      Graying of vision",
"     </li>",
"     <li>",
"      Hemianopia",
"     </li>",
"     <li>",
"      Bilateral visual blurring",
"     </li>",
"     <li>",
"      Syncope",
"     </li>",
"     <li>",
"      Tinnitus",
"     </li>",
"     <li>",
"      Hearing loss",
"     </li>",
"     <li>",
"      Bilateral brachial diplegia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Upper extremity exercise increases blood flow to the arm and, by decreasing arm arterial resistance, can precipitate central nervous system symptoms. The presence of collateral blood supply and the capacity to increase collateral flow may be the principal determinants of which patients develop neurologic symptoms in this setting. Vertebral artery compression and neurologic symptoms can also occur with head movements, usually rotation of the face towards the opposite side [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/23\">",
"     23",
"    </a>",
"    ]. This association can usually be detected by a careful history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;On examination, the patient often has a significant difference in brachial systolic blood pressure (&gt;15 mmHg differential) between the affected and normal arm. In addition, simultaneous palpation of both radial artery pulses will usually disclose a decrease in amplitude and delay in arrival on the affected side (",
"    <a class=\"graphic graphic_waveform graphicRef61635 \" href=\"mobipreview.htm?3/41/3728\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The carotid arteries should be carefully examined, using palpation and auscultation, for evidence of occlusive arterial disease and auscultation over the suboccipital region for vertebral artery bruits should be performed. It is important to examine the subclavian arteries in the supraclavicular fossa using palpation (pulse character and thrills) and auscultation for bruits.",
"   </p>",
"   <p>",
"    Other parts of the physical examination should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Performance of thoracic outlet maneuvers to exclude other causes of a subclavian stenosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2906?source=see_link&amp;anchor=H24#H24\">",
"       \"Brachial plexus syndromes\", section on 'Thoracic outlet syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All major pulses should be palpated. The presence of multiple pulse deficits (subclavian and carotid) raises the possibility of Takayasu's disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=see_link\">",
"       \"Clinical features and diagnosis of Takayasu arteritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The skin of the hands and nail beds of the affected extremity should be thoroughly examined. Atheroembolism from atherosclerotic lesions of the subclavian artery may result in blue fingers, livedo reticularis, digital ischemia or ulceration or splinter hemorrhages under the nail beds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive evaluation of the cerebrovascular and upper extremity arterial circulation utilizing continuous wave Doppler, duplex ultrasonography, transcranial Doppler, magnetic resonance imaging and magnetic resonance angiography or CT angiography is adequate to establish the diagnosis in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Continuous wave Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertebral steal, as determined by continuous wave Doppler, is apparent in approximately 6 percent of patients with asymptomatic neck bruits but, in one series, none of the patients developed symptoms during a two-year follow-up period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/21\">",
"     21",
"    </a>",
"    ]. Continuous wave Doppler examination has shown that, even when reversed flow occurs in the vertebral artery, antegrade basilar arterial flow persists and may even be increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Duplex ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplex ultrasonography (combined two-dimensional ultrasound and pulsed-wave Doppler) can readily diagnose and semi-quantify proximal subclavian artery stenoses and demonstrate reversal of flow, if present, in the ipsilateral vertebral artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80201 \" href=\"mobipreview.htm?23/60/24527\">",
"     image 1",
"    </a>",
"    ). Duplex ultrasound can also evaluate the origin of the vertebral artery for evidence of occlusive disease, and also diagnose significant extracranial carotid artery occlusive disease.",
"   </p>",
"   <p>",
"    When severe stenosis (&gt;80 percent narrowing) of the proximal subclavian artery is present, 65 percent of patients have permanent flow reversal in the ipsilateral vertebral artery, and 30 percent have intermittent flow reversal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. In patients with moderate subclavian artery stenosis (approximately 50 percent narrowing), flow reversal in the vertebral artery is permanent in 56 percent, and intermittent (ie, \"to and fro\" waveform pattern on duplex) in 36 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1599269568\">",
"    <span class=\"h2\">",
"     Transcranial Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;When flow reversal of the vertebral artery is identified, some authors have suggested transcranial Doppler (TCD) to evaluate the direction of flow in the basilar artery. In one study of patients with flow reversal of the vertebral artery ipsilateral to a subclavian",
"    <span class=\"nowrap\">",
"     stenosis/occlusion,",
"    </span>",
"    76 percent of patients had antegrade flow in the basilar artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with antegrade flow are not likely to have vertebrobasilar ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Magnetic resonance angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance angiography (MRA) is an accurate and reliable alternative test in patients with suspected subclavian steal syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/25\">",
"     25",
"    </a>",
"    ]. Contrast-enhanced MRA enables visualization and characterization of the majority of supraaortic arteries, with diagnostic or excellent image quality and diagnostic values comparable to those obtained using CT angiography or standard angiography for detection of arterial stenoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/26\">",
"     26",
"    </a>",
"    ]. Flow reversal in the vertebral artery ipsilateral to a subclavian stenosis is inferred from presence of vertebral artery patency on three-dimensional contrast-enhanced MRA but absence of flow on time-of-flight localizer images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition to evaluation of the extracranial vessels, MRA also provides detailed anatomic information of the intracranial cerebrovascular circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     CT angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;When ultrasound techniques are inconclusive and contrast-enhanced MRA is contraindicated, CT angiography may be used for exclusion or quantification of subclavian artery stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/23,28\">",
"     23,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Contrast angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclavian artery stenosis and reversal of flow in the ipsilateral vertebral artery, if present, can be demonstrated by conventional cerebral angiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63380 \" href=\"mobipreview.htm?23/46/24292\">",
"     image 2",
"    </a>",
"    ). Concurrent intracranial atherosclerotic disease and anomalies of the circle of Willis are also identified.",
"   </p>",
"   <p>",
"    Retrospective angiographic studies of patients with symptomatic cerebrovascular disease have found that 17 to 23 percent of patients have a severe proximal subclavian stenosis; however, only 2.5 to 6 percent of these patients have reversed flow in the ipsilateral vertebral artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/23,29\">",
"     23,29",
"    </a>",
"    ]. Therefore, steal as defined by angiography occurs in only a minority of patients with subclavian stenosis. However, as noted above, studies using Doppler techniques have demonstrated that retrograde flow in the vertebral arteries is much more common than had been suspected from angiographic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclavian artery stenosis is associated with an increased risk of both overall mortality and mortality related to cardiovascular disease (CVD). This observation is supported by results from a study of 157 patients with subclavian artery stenosis, which was diagnosed by a brachial systolic pressure difference &ge;15 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/30\">",
"     30",
"    </a>",
"    ]. After adjusting for age, gender, ethnicity, cohort of origin, CVD risk factors (smoking, hypertension, diabetes, lipids, and body mass index), and lipid-lowering and antiplatelet therapies, the presence of subclavian stenosis was significantly associated with increased total mortality and CVD mortality (hazard ratios, 1.40 and 1.57, respectively).",
"   </p>",
"   <p>",
"    Despite the reversal of vertebral artery blood flow, prospective studies of patients with documented subclavian steal have demonstrated a very low incidence of posterior circulation ischemic events. As an example, one study followed patients with severe subclavian artery stenosis for three years. The majority (80 percent) of patients had reversed vertebral flow, but no neurologic symptoms developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/21\">",
"     21",
"    </a>",
"    ]. None of these patients had reversed or bidirectional basilar arterial flow, either at rest, or following the subclavian steal test of inflating a blood pressure cuff on the ipsilateral arm to greater than systolic pressure for three minutes. Antegrade blood flow in the basilar artery was present in most patients regardless of the flow pattern in the vertebral artery.",
"   </p>",
"   <p>",
"    Patients with subclavian stenosis are more likely to develop hemispheric ischemia due to concurrent progressive carotid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/20\">",
"     20",
"    </a>",
"    ]. Collateral pathways are usually compromised in symptomatic patients, placing them at increased risk, principally from carotid territory cerebrovascular events.",
"   </p>",
"   <p>",
"    There is also a subset of patients with primary proximal subclavian artery ulcerative and stenotic lesions who embolize through the ipsilateral vertebral artery, leading to transient vertebrobasilar ischemia that is not due to the steal phenomenon.",
"   </p>",
"   <p>",
"    Bilateral vertebral flow reversal may be associated with an increased risk of nonlateralizing cerebral ischemia. In one study, brainstem dysfunction from upper extremity exercise was seen only in patients with bilateral reversed flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/31\">",
"     31",
"    </a>",
"    ]. However, persistent retrograde flow in the basilar artery, with collateral blood supply from the internal carotid arteries, has been reported in a patient without any neurologic or upper extremity symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclavian",
"    <span class=\"nowrap\">",
"     stenosis/occlusion",
"    </span>",
"    is a marker for atherosclerotic disease (eg, carotid, coronary, lower extremity arteries) and future adverse cardiovascular events. Thus, the detection of subclavian stenosis identifies patients who may benefit from secondary prevention measures such as the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Control of hypertension",
"     </li>",
"     <li>",
"      Lipid modification",
"     </li>",
"     <li>",
"      Glycemic control in diabetes",
"     </li>",
"     <li>",
"      Smoking cessation",
"     </li>",
"     <li>",
"      Therapeutic lifestyle changes",
"     </li>",
"     <li>",
"      Antiplatelet therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential importance of these measures is illustrated by the findings of a prospective observational cohort study of 2420 patients with peripheral arterial disease who were followed for a median of eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/33\">",
"     33",
"    </a>",
"    ]. Interventions with statins, beta blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and angiotensin converting enzyme (ACE) inhibitors were each associated with a significantly reduced risk of long-term mortality. Risk factor modification and secondary prevention of cardiovascular disease and stroke is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to therapy of subclavian steal associated with symptoms varies with the clinical setting. In many patients, symptoms improve over time without treatment. Interventional treatment is not usually warranted in patients with asymptomatic subclavian",
"    <span class=\"nowrap\">",
"     stenosis/occlusion.",
"    </span>",
"    Symptomatic patients with proximal subclavian artery ulcerative occlusive disease complicated by embolization, in the absence of other significant cerebrovascular disease, can be successfully treated by surgical removal or exclusion of the proximal subclavian lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/34\">",
"     34",
"    </a>",
"    ]. Percutaneous angioplasty and stenting (with embolic protection) for embolism related to proximal subclavian artery is appropriate for patients with short",
"    <span class=\"nowrap\">",
"     stenosis/occlusion",
"    </span>",
"    at the origin of the subclavian artery. We prefer surgical revascularization if percutaneous treatment will jeopardize the integrity of the vertebral artery. Patients with unacceptable surgical risk or anatomy unfavorable for intervention can be treated with antiplatelet therapy (and possibly oral anticoagulation), but no prospective trials have evaluated the effectiveness of this option.",
"   </p>",
"   <p>",
"    Extra-anatomic revascularization (eg, carotid-subclavian bypass, carotid transposition) is the most common form of surgical correction for symptomatic subclavian artery stenosis. Overall patency rates of 95 percent at one year, 86 percent at three years, and 73 percent at five years have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/31\">",
"     31",
"    </a>",
"    ]. Patency at five years is significantly higher for procedures utilizing the common carotid artery as the donor vessel compared with those using the contralateral subclavian or axillary arteries (83 versus 46 percent, p&lt;0.01) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/31\">",
"     31",
"    </a>",
"    ]. Axillo-axillary bypass is an alternative method for revascularization in patients at high surgical risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited and no randomized trials are available, retrospective observational studies suggest that percutaneous transluminal angioplasty and stenting is safe in patients with appropriate anatomy (short proximal stenosis or occlusion). Immediate technical success is achieved in greater than 93 percent of patients with failures usually related to an inability to cross occlusive lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Five-year primary patency rates are about 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/37\">",
"     37",
"    </a>",
"    ]. Sustained resolution of ischemic symptoms is observed in most patients (&gt;95 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/8,36-38\">",
"     8,36-38",
"    </a>",
"    ]. Angioplasty alone has inferior outcomes compared with angioplasty and stenting, particularly when recanalizing subclavian occlusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The combined stroke and death rate related to percutaneous intervention was 3.6 percent in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a continuous (compared with intermittent) subclavian and coronary artery steal may have a higher risk of subclavian artery restenosis following endovascular therapy. A retrospective study of 42 patients treated with angioplasty and stenting for coronary subclavian steal syndrome found that the rate of restenosis was higher in patients with a continuous (compared with intermittent) subclavian and coronary steal (41 and 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/42\">",
"     42",
"    </a>",
"    ]. Symptoms due to significant (&gt;70 percent) recurrent stenosis or obstruction occur in approximately 10 percent of patients, and are typically treated with repeat angioplasty; however, surgery may be required in up to 5 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical treatment for patients with a subclavian steal and coexisting severe carotid stenosis is more controversial. Because a significant percentage of patients with subclavian steal have concomitant severe extracranial atherosclerotic disease, carotid artery endarterectomy should generally be performed first and may result in symptomatic improvements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36471/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17205936\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subclavian steal refers to a phenomenon of flow reversal in the vertebral artery ipsilateral to a hemodynamically significant stenosis or occlusion of the subclavian artery. Subclavian steal represents an appropriate physiological compensation to proximal subclavian artery disease. Subclavian steal syndrome refers to the presence of significant symptoms due to arterial insufficiency. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A hemodynamically significant stenosis proximal to the origin of the vertebral artery results in lower pressure in the distal subclavian artery. As a result, blood flows from the contralateral vertebral artery to the basilar artery, and blood may flow in a retrograde direction down the ipsilateral vertebral artery, away from the brainstem (",
"      <a class=\"graphic graphic_figure graphicRef62622 \" href=\"mobipreview.htm?31/29/32210\">",
"       figure 1",
"      </a>",
"      ). In patients with an internal mammary artery bypass graft to the heart, proximal ipsilateral stenosis relative to the graft may reverse and \"steal\" flow from the coronary circulation during upper extremity exercise (ie, coronary-subclavian steal syndrome) (",
"      <a class=\"graphic graphic_figure graphicRef76733 \" href=\"mobipreview.htm?39/22/40288\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with subclavian artery stenosis are asymptomatic. For many, subclavian artery occlusive disease is found incidentally. When symptoms occur, they are due to arm ischemia or symptoms of vertebrobasilar ischemia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulse examination and duplex ultrasound evaluation of the cerebrovascular and upper extremity arterial circulation establish the diagnosis in most patients. On examination, the patient often has a significant difference in brachial systolic blood pressure (&gt;15 mmHg differential) between the affected and normal arm. &nbsp;If needed, more advanced imaging that includes the aortic arch vessels and intracranial vessels can be accomplished with magnetic resonance imaging, computed tomographic angiography, or standard arteriography. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subclavian",
"      <span class=\"nowrap\">",
"       stenosis/occlusion",
"      </span>",
"      is a marker for atherosclerotic disease (eg, carotid, coronary, lower extremity arteries) and is associated with an increased risk of morbidity and mortality related to cardiovascular disease (CVD). Patients with atherosclerosis benefit from secondary prevention measures (ie,&nbsp;treatment of modifiable cardiovascular risk factors). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We treat patients with subclavian steal syndrome. The choice of intervention (surgical, endovascular) depends upon the patient&rsquo;s specific anatomy, the presence of concomitant ipsilateral carotid disease, and the patient&rsquo;s overall medical status. Patients with subclavian steal syndrome who are not candidates for intervention are treated with antithrombotic therapy. For asymptomatic patients, the emphasis is on&nbsp;secondary prevention. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/1\">",
"      CONTORNI L. [The vertebro-vertebral collateral circulation in obliteration of the subclavian artery at its origin]. Minerva Chir 1960; 15:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/2\">",
"      REIVICH M, HOLLING HE, ROBERTS B, TOOLE JF. Reversal of blood flow through the vertebral artery and its effect on cerebral circulation. N Engl J Med 1961; 265:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/3\">",
"      Fisher, CM. A new vascular syndrome: \"The subclavian steal.\" N Engl J Med 1961; 265:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/4\">",
"      PATEL A, TOOLE JF. SUBCLAVIAN STEAL SYNDROME--REVERSAL OF CEPHALIC BLOOD FLOW. Medicine (Baltimore) 1965; 44:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/5\">",
"      Toole JF, McGraw CP. The steal syndromes. Annu Rev Med 1975; 26:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/6\">",
"      Ochi M, Yamauchi S, Yajima T, et al. Simultaneous subclavian artery reconstruction in coronary artery bypass grafting. Ann Thorac Surg 1997; 63:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/7\">",
"      Takach TJ, Beggs ML, Nykamp VJ, Reul GJ Jr. Concomitant cerebral and coronary subclavian steal. Ann Thorac Surg 1997; 63:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/8\">",
"      Nguyen NH, Reeves F, Therasse E, et al. Percutaneous transluminal angioplasty in coronary-internal thoracic-subclavian steal syndrome. Can J Cardiol 1997; 13:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/9\">",
"      Rogers JH, Calhoun RF 2nd. Diagnosis and management of subclavian artery stenosis prior to coronary artery bypass grafting in the current era. J Card Surg 2007; 22:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/10\">",
"      Hwang HY, Kim JH, Lee W, et al. Left subclavian artery stenosis in coronary artery bypass: prevalence and revascularization strategies. Ann Thorac Surg 2010; 89:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/11\">",
"      KESTELOOT H, VANHOUTE O. REVERSED CIRCULATION THROUGH THE VERTEBRAL ARTERY. Acta Cardiol 1963; 18:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/12\">",
"      Yoneda S, Nukada T, Tada K, et al. Subclavian steal in Takayasu's arteritis. A hemodynamic study by means of ultrasonic Doppler flowmetry. Stroke 1977; 8:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/13\">",
"      Saalouke MG, Perry LW, Breckbill DL, et al. Cerebrovascular abnormalities in postoperative coarctation of aorta. Four cases demonstrating left subclavian steal on aortography. Am J Cardiol 1978; 42:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/14\">",
"      Kurlan R, Krall RL, Deweese JA. Vertebrobasilar ischemia after total repair of tetralogy of Fallot: significance of subclavian steal created by Blalock-Taussig anastomosis. Vertebrobasilar ischemia after correction of tetralogy of Fallot. Stroke 1984; 15:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/15\">",
"      MASSUMI RA. THE CONGENITAL VARIETY OF THE \"SUBCLAVIAN STEAL\" SYNDROME. Circulation 1963; 28:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/16\">",
"      Luetmer PH, Miller GM. Right aortic arch with isolation of the left subclavian artery: case report and review of the literature. Mayo Clin Proc 1990; 65:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/17\">",
"      Kajinami K, Mori K, Masuda S, et al. Asymptomatic congenital subclavian steal in a young male patient with right aortic arch. Chest 1990; 97:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/18\">",
"      Savastano S, Feltrin GP, Chiesura-Corona M, Miotta D. Cerebral ischemia due to congenital malformations of brachiocephalic arteries--case reports. Angiology 1992; 43:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/19\">",
"      Bornstein NM, Krajewski A, Norris JW. Basilar artery blood flow in subclavian steal. Can J Neurol Sci 1988; 15:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/20\">",
"      Hennerici M, Klemm C, Rautenberg W. The subclavian steal phenomenon: a common vascular disorder with rare neurologic deficits. Neurology 1988; 38:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/21\">",
"      Bornstein NM, Norris JW. Subclavian steal: a harmless haemodynamic phenomenon? Lancet 1986; 2:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/22\">",
"      Lord RS, Adar R, Stein RL. Contribution of the circle of Willis to the subclavian steal syndrome. Circulation 1969; 40:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/23\">",
"      Theron J, Melan&ccedil;on D, Ethier R. \"Pre\" subclavian steal syndromes and their treatment by angioplasty. Hemodynamic classification of subclavian artery stenoses. Neuroradiology 1985; 27:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/24\">",
"      Harper C, Cardullo PA, Weyman AK, Patterson RB. Transcranial Doppler ultrasonography of the basilar artery in patients with retrograde vertebral artery flow. J Vasc Surg 2008; 48:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/25\">",
"      Van Grimberge F, Dymarkowski S, Budts W, Bogaert J. Role of magnetic resonance in the diagnosis of subclavian steal syndrome. J Magn Reson Imaging 2000; 12:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/26\">",
"      Nael K, Villablanca JP, Pope WB, et al. Supraaortic arteries: contrast-enhanced MR angiography at 3.0 T--highly accelerated parallel acquisition for improved spatial resolution over an extended field of view. Radiology 2007; 242:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/27\">",
"      Sheehy N, MacNally S, Smith CS, et al. Contrast-enhanced MR angiography of subclavian steal syndrome: value of the 2D time-of-flight \"localizer\" sign. AJR Am J Roentgenol 2005; 185:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/28\">",
"      Park KH, Lee HY, Lim C, et al. Clinical impact of computerised tomographic angiography performed for preoperative evaluation before coronary artery bypass grafting. Eur J Cardiothorac Surg 2010; 37:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/29\">",
"      Fields WS, Lemak NA. Joint Study of extracranial arterial occlusion. VII. Subclavian steal--a review of 168 cases. JAMA 1972; 222:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/30\">",
"      Aboyans V, Criqui MH, McDermott MM, et al. The vital prognosis of subclavian stenosis. J Am Coll Cardiol 2007; 49:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/31\">",
"      Salam TA, Lumsden AB, Smith RB 3rd. Subclavian artery revascularization: a decade of experience with extrathoracic bypass procedures. J Surg Res 1994; 56:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/32\">",
"      Klingelh&ouml;fer J, Conrad B, Benecke R, Frank B. Transcranial Doppler ultrasonography of carotid-basilar collateral circulation in subclavian steal. Stroke 1988; 19:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/33\">",
"      Feringa HH, van Waning VH, Bax JJ, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 2006; 47:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/34\">",
"      Walker PM, Paley D, Harris KA, et al. What determines the symptoms associated with subclavian artery occlusive disease? J Vasc Surg 1985; 2:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/35\">",
"      Chang JB, Stein TA, Liu JP, Dunn ME. Long-term results with axillo-axillary bypass grafts for symptomatic subclavian artery insufficiency. J Vasc Surg 1997; 25:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/36\">",
"      Hadjipetrou P, Cox S, Piemonte T, Eisenhauer A. Percutaneous revascularization of atherosclerotic obstruction of aortic arch vessels. J Am Coll Cardiol 1999; 33:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/37\">",
"      Wang KQ, Wang ZG, Yang BZ, et al. Long-term results of endovascular therapy for proximal subclavian arterial obstructive lesions. Chin Med J (Engl) 2010; 123:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/38\">",
"      Mahmud E, Cavendish JJ, Salami A. Current treatment of peripheral arterial disease: role of percutaneous interventional therapies. J Am Coll Cardiol 2007; 50:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/39\">",
"      De Vries JP, Jager LC, Van den Berg JC, et al. Durability of percutaneous transluminal angioplasty for obstructive lesions of proximal subclavian artery: long-term results. J Vasc Surg 2005; 41:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/40\">",
"      Patel SN, White CJ, Collins TJ, et al. Catheter-based treatment of the subclavian and innominate arteries. Catheter Cardiovasc Interv 2008; 71:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/41\">",
"      Sixt S, Rastan A, Schwarzw&auml;lder U, et al. Results after balloon angioplasty or stenting of atherosclerotic subclavian artery obstruction. Catheter Cardiovasc Interv 2009; 73:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/42\">",
"      Filippo F, Francesco M, Francesco R, et al. Percutaneous angioplasty and stenting of left subclavian artery lesions for the treatment of patients with concomitant vertebral and coronary subclavian steal syndrome. Cardiovasc Intervent Radiol 2006; 29:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36471/abstract/43\">",
"      Smith JM, Koury HI, Hafner CD, Welling RE. Subclavian steal syndrome. A review of 59 consecutive cases. J Cardiovasc Surg (Torino) 1994; 35:11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8183 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-A7B55BFC08-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36471=[""].join("\n");
var outline_f35_39_36471=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17205936\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Coronary-subclavian steal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Continuous wave Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Duplex ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1599269568\">",
"      Transcranial Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Magnetic resonance angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CT angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Contrast angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17205936\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8183\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8183|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/60/24527\" title=\"diagnostic image 1\">",
"      Vertebral artery flow in subclavian steal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/46/24292\" title=\"diagnostic image 2\">",
"      Angio subclavian steal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8183|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/29/32210\" title=\"figure 1\">",
"      Subclavian steal physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/22/40288\" title=\"figure 2\">",
"      Coronary steal physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/58/18338\" title=\"figure 3\">",
"      Anatomy of the thoracic outlet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8183|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?3/41/3728\" title=\"waveform 1\">",
"      Radial pulse delay in subclavian steal syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=related_link\">",
"      Clinical features and diagnosis of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28794?source=related_link\">",
"      Overview of the management of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39273?source=related_link\">",
"      Posterior circulation cerebrovascular syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_39_36472="Renal transplantation in diabetic nephropathy";
var content_f35_39_36472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal transplantation in diabetic nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/39/36472/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/39/36472/contributors\">",
"     Garry S Tobin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/39/36472/contributors\">",
"     Christina Klein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/39/36472/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/39/36472/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/39/36472/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/39/36472/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/39/36472/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/39/36472/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/39/36472/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in Western societies and accounts for approximately 40 to 45 percent of cases of ESRD in the United States. Diabetic nephropathy was the etiology of ESRD in approximately 23 percent of kidney transplant recipients transplanted in the United States in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetes presents particular challenges both in the pretransplant evaluation and after transplantation. These challenges are related to the high incidence of cardiovascular disease among diabetic patients, and the increased risk of bacterial and fungal infections compared with nondiabetic transplant recipients.",
"   </p>",
"   <p>",
"    In addition, glycemic control is often more difficult after transplantation. This is because immunosuppressive regimens used after transplantation have detrimental effects on pancreatic beta cell function and peripheral insulin action, which make it difficult to achieve target glucose levels and prevent the recurrence of the diabetic lesions in the transplanted kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major issues related to renal transplantation in diabetic patients with ESRD are discussed in this topic review. The role of combined kidney-pancreas transplantation is discussed separately. New onset diabetes that occurs after renal transplantation is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/19/41272?source=see_link\">",
"     \"Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/16/7434?source=see_link\">",
"     \"Patient selection for and immunologic issues relating to kidney-pancreas transplantation in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26250?source=see_link\">",
"     \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENEFITS OF TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney transplantation is the preferred renal replacement therapy for diabetic patients with ESRD, since it generally results in better survival and quality of life than dialysis. We recommend that diabetic patients who are eligible receive a kidney transplant rather than continue dialysis. Preemptive kidney transplantation rather than initiation of dialysis followed by transplantation is preferred, and if possible, a living donor kidney is preferred to a deceased donor kidney. We also suggest that all wait-listed diabetic patients register on both the standard-donor wait list and the expanded-criteria donor (ECD) wait list. Although ECD kidneys do not meet the criteria for standard donor kidneys, diabetic patients who receive them are likely to live longer than if they remained on dialysis.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212465755\">",
"    <span class=\"h2\">",
"     Transplantation versus dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For eligible candidates, we recommend kidney transplantation rather than dialysis. Compared with dialysis, transplantation is associated with a much better survival among all patients with ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/3-10\">",
"     3-10",
"    </a>",
"    ]. In one of the largest, most comprehensive studies to date, survival analysis using data from the United States Renal Data System (USRDS) was performed on nearly 230,000 dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/6\">",
"     6",
"    </a>",
"    ]; among the 46,000 placed on a waiting list for transplantation, 23,000 subsequently underwent a first cadaveric transplant. Despite a significantly",
"    <em>",
"     increased",
"    </em>",
"    short-term mortality following surgery, the long-term risk of death was much lower among transplant recipients compared with patients accepted for transplantation but who had not yet received an allograft. As an example, at three to four years the mortality risk was nearly 70 percent lower among transplant recipients compared with wait-list patients (relative risk of 0.32).",
"   </p>",
"   <p>",
"    Diabetes was the cause of ESRD among 33 percent of the 46,164 patients on the transplant waiting list and 31 percent of the 23,275 transplant recipients. At 18 months post-transplantation, the subset of 7200 diabetic transplant recipients had a 73 percent reduced risk of death compared with the approximately 15,000 diabetic wait-listed patients (relative risk 0.27, 95% CI, 0.24-0.30). The projected increase in life was 11 years among diabetic patients who undergo transplantation compared with diabetics who remain on the waiting list.",
"   </p>",
"   <p>",
"    Another study from Scotland reported the survival of 1732 patients wait-listed for a first kidney transplant in 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/9\">",
"     9",
"    </a>",
"    ]. Among approximately 250 diabetic patients, at 12 months after transplantation, the risk of death was lower with renal transplantation compared with dialysis (relative risk 0.33, 95% CI 0.15-0.74). Projected life expectancy was significantly higher in those who underwent transplantation (17.2 versus 5.8 years).",
"   </p>",
"   <p>",
"    The reduction in mortality among transplant recipients compared with dialysis patients is due in part to a decrease in cardiovascular events especially among diabetic patients. Transplantation reduces the risk of fatal and non-fatal cardiovascular complications compared with long-term dialysis among patients selected to be suitable transplant candidates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212465762\">",
"    <span class=\"h2\">",
"     Preemptive transplantation and living donor versus deceased kidneys",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend preemptive kidney transplantation if possible, rather than initiation of dialysis followed by transplantation. Among all patients with chronic kidney disease (CKD), evidence suggests that preemptive kidney transplantation (ie, before dialysis is required) leads to substantial improvements in patient survival when compared with transplantation after a period of dialysis therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11224?source=see_link&amp;anchor=H2#H2\">",
"     \"Dialysis issues prior to and after renal transplantation\", section on 'Preemptive transplantation and outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited evidence also suggests that diabetic patients with CKD have a survival advantage with preemptive transplantation. In an analysis of 73,103 patients registered in the USRDS database including almost 20,000 diabetic patients, compared with preemptive transplantation, there was a relative increase in mortality risk after transplantation of 21, 28, 41, 53, and 72 percent among those with waiting times of 6 to 12 months, 12 to 24 months, 24 to 36, 36 to 48, and over 48 months, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, relative to preemptive transplants, waiting times of 0 to 6 months, 6 to 12 months, 12 to 24 months, and over 24 months conferred a 17, 37, 55, and 68 percent relative increase in risk for death-censored graft loss after transplantation, respectively. The association between mortality risk and graft loss and increasing time on dialysis was observed for all subgroups defined by the cause of ESRD, including patients with diabetes.",
"   </p>",
"   <p>",
"    It is not clear whether the benefits of preemptive transplantation among diabetic patients are achieved when either living donor or deceased donor kidneys are used. In the study cited above, preemptive transplantation was associated with better patient and allograft survival among both living donor kidney and deceased donor recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/17\">",
"     17",
"    </a>",
"    ]. However, another study has suggested that the benefit of preemptive transplantation is limited to living donor recipients. In a retrospective study of over 20,000 diabetic patients a lower mortality was observed among recipients of preemptive kidney transplants from living donors (with relative risks of 0.57 and 0.65 for recipients with type 1 and type 2 diabetes, respectively) but this association was NOT observed among either type 1 or type 2 diabetic recipients of cadaveric donor kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/20\">",
"     20",
"    </a>",
"    ]. In practice, preemptive transplantation with a deceased donor kidney is rarely performed because of prolonged waiting-list times. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11240?source=see_link&amp;anchor=H13#H13\">",
"     \"The kidney transplant waiting list\", section on 'Access to the waiting list'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Living donor kidney transplantation provides better outcomes including graft and patient survival compared with simultaneous kidney-pancreas transplantation. Issues surrounding patient survival relating to kidney-pancreas transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/19/41272?source=see_link\">",
"     \"Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212466317\">",
"    <span class=\"h2\">",
"     Expanded criteria kidneys",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that all wait-listed diabetic patients register on both the standard-donor wait list and the expanded-criteria donor (ECD) wait list.",
"   </p>",
"   <p>",
"    ECD kidneys are those from either a brain-dead donor older than 60 years, or a donor older than 50 years with at least two of the following: hypertension, serum creatinine greater than 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    or cerebrovascular cause of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/21\">",
"     21",
"    </a>",
"    ]. Among all dialysis patients, transplantation of an ECD kidney is associated with a higher risk of allograft failure compared with transplantation of a standard donor kidney, but with a lower mortality compared with remaining on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/21\">",
"     21",
"    </a>",
"    ]. Upon registering on the deceased donor waiting list, potential recipients must state whether they will accept offers of an ECD kidney.",
"   </p>",
"   <p>",
"    The potential benefit gained by all ECD-transplant recipients depends upon the patient&rsquo;s age and on the anticipated waiting time for a deceased donor kidney; in general, older patients incur a survival benefit with ECD kidneys, whereas patients younger than 40 years are better off waiting for a standard kidney. This was shown in an in-depth analysis of the Scientific Registry of Transplant Recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/21\">",
"     21",
"    </a>",
"    ]. Although transplantation of an ECD kidney was associated with a survival benefit overall, subgroup analysis demonstrated a significant benefit for older than but not younger than 40 years. In addition, the survival benefit among patients older than 40 was not observed among those who were wait-listed at organ procurement organizations with short or medium wait-list times. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11240?source=see_link&amp;anchor=H12#H12\">",
"     \"The kidney transplant waiting list\", section on 'Expanded donor kidneys'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, among diabetic patients of any age, there may be a survival advantage gained from accepting an ECD kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In the study cited above, among all diabetic patients, there was a 23 percent reduction in mortality among recipients of an ECD transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/21\">",
"     21",
"    </a>",
"    ]. By contrast to non-diabetic patients older than 40, a survival benefit was even observed among diabetic patients older than 40 who were wait-listed at organ procurement organizations with short or medium wait-list times (relative risk, 0.77, 95% CI 0.64 -0.94). In addition, among 2016 diabetic patients who were younger than 40 years and in an organ procurement organization with a short or medium waiting time, transplantation of an ECD kidney was associated with a 41 percent reduction in mortality (relative risk 0.59, 95% CI 0.30&ndash;1.16).",
"   </p>",
"   <p>",
"    Similarly, diabetic patients benefit from transplantation of kidneys donated after cardiac death, which are generally perceived to have worse outcomes compared with standard criteria kidneys donated after non cardiac death. This was shown in an observational cohort study of 2575 ESRD patients that evaluated the mortality risk of those who received a standard criteria kidney donated after cardiac death versus patients who continued on dialysis and waited for a standard criteria kidney donated after brain death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/23\">",
"     23",
"    </a>",
"    ]. Approximately 29 percent of patients had diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension. Compared to those who remained on dialysis, mortality was significantly lower among patients who received a kidney donated after cardiac death (hazard ratio 0.44, 95% CI 0.24-0.80).",
"   </p>",
"   <p>",
"    Thus survival of diabetic patients, especially those over age 40, is generally improved following transplantation of ECD kidneys compared with remaining on dialysis while awaiting a standard kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRETRANSPLANT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;General issues related to pretransplant evaluation of all patients with chronic kidney disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .) The following section reviews several issues of particular concern among patients with diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Timing of referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the Kidney Disease Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (K/DOQI)",
"    </span>",
"    guidelines that recommend referral of chronic kidney disease (CKD) patients to transplant centers when estimated glomerular filtration rate (GFR) is less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cardiac evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease remains the most common cause of death following kidney transplantation among diabetic patients, and the highest rates of adverse cardiac events are observed in the early post-transplant period. Diabetic transplant candidates are screened for coronary heart disease in order to identify modifiable cardiac conditions and potentially reduce morbidity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mortality on the waitlist and following transplantation. Additionally, the evaluation may identify patients who have limited expected survival due to severe cardiac disease; such patients should not undergo transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617455917\">",
"    <span class=\"h3\">",
"     Prevalence of cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among all kidney transplant candidates, the incidence of coronary heart disease varies based on the specific population studied and the screening method utilized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported incidence of significant cardiac disease among asymptomatic diabetic patients who are evaluated for transplantation is approximately 33 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 155 consecutive diabetic patients evaluated for transplant between 1999 and 2004, angiographic evidence of significant coronary heart disease (&gt;50 percent luminal diameter stenosis) was found in 69 patients (45 percent), with only 26 (17 percent) having history of angina [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/25\">",
"       25",
"      </a>",
"      ]. The only risk factor of significance was age, with no patient under the age of 35 (n = 11) with significant coronary heart disease. The degree of hypercholesterolemia, hypertension, and smoking history did not differ between those with and without documented coronary disease.",
"     </li>",
"     <li>",
"      Among 97 asymptomatic diabetic transplant candidates, 33 and 48 percent of type 1 and 2 diabetes patients had coronary heart disease, respectively, as defined by &gt;70 percent stenosis in one or more coronary arteries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/26\">",
"       26",
"      </a>",
"      ]. Factors that predicted significant coronary heart disease included obesity (BMI &gt;25, relative risk (RR) of 4.8), increased age (&gt;47 years, RR of 3.0), and smoking history (2 percent increase in risk per pack-year of smoking).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In light of the high prevalence of asymptomatic cardiovascular disease, preoperative screening is routine at most transplant centers, although there have been attempts to develop clinical algorithms to identify high risk candidates. As an example, one such algorithm was developed and validated in a retrospective study of type 1 diabetic patients who were being evaluated for either solitary kidney or combined kidney pancreas transplantation between 1991 and 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Patients were characterized as high risk based upon the presence of any of the following risk factors: age &ge;45 years, smoking history &ge;5 pack-years, diabetes duration &ge;25 years, or ST-T segment abnormalities on resting electrocardiogram.",
"   </p>",
"   <p>",
"    Among 84 high risk patients who underwent angiography, significant coronary heart disease was detected in 31 (37 percent). At a median follow up of 47 months, six cardiac deaths occurred in the high risk group and no deaths occurred in the low risk group, although survival among the high risk patients was not different among those with or without significant disease detected by angiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2217195\">",
"    <span class=\"h3\">",
"     Approach to evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to the diabetic kidney transplant recipient is not clear and there are no reliable comparative studies in this cohort to guide the evaluation. Some clinicians base their approach on the age of the patient, duration of diabetes mellitus and smoking history, and presence or absence of electrocardiographic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We perform noninvasive cardiac testing in all diabetic patients regardless of age. We do not routinely perform cardiac catheterization in all diabetic patients, unless they have symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs consistent with coronary heart disease, history of myocardial infarction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unstable angina. The data on patient survival does not unequivocally support the use of routine pretransplant cardiac catheterization, especially given the potential adverse effects of cardiac catheterization, including contrast nephropathy which could result in the earlier initiation of dialysis than may have occurred otherwise. Some clinicians, however, use routine cardiac catheterization among all diabetic patients older than 45 years of age.",
"   </p>",
"   <p>",
"    The accuracy and predictive value of noninvasive testing is only fair in the ESRD population. We generally use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography rather than other noninvasive tests since data have suggested that this modality is most accurate among ESRD patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33559?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\", section on 'Stress tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All diabetic transplant candidates are evaluated with a history, physical examination, electrocardiogram, and chest radiograph.",
"     </li>",
"     <li>",
"      Diabetic patients who have symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs consistent with coronary heart disease or a history of myocardial infarction undergo cardiac catheterization unless they recently underwent successful revascularization. As in the non-ESRD population, patients with unstable angina should undergo cardiac catheterization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link&amp;anchor=H23#H23\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Immediate angiography and revascularization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A screening",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiography is performed among all diabetic patients who do not undergo initial screening coronary angiography. If positive, the decision to proceed with angiography and possible angioplasty or surgery is usually made in conjunction with the patients' cardiologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, the overall accuracy and predictive value of noninvasive testing is only fair in the ESRD population, with accuracy of the different non-invasive imaging tests being center-specific and dependent upon the expertise of the examiner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. There are also problems associated with advanced kidney disease, including baseline abnormalities on the electrocardiogram and thallium scintigraphy and a frequent inability of patients to perform adequately during an exercise test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, exercise electrocardiography and exercise echocardiography are not generally recommended because of poor exercise capabilities in the dialysis population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/30\">",
"     30",
"    </a>",
"    ]. The optimal approach to non-invasive imaging in dialysis patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33559?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\", section on 'Stress tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among transplantation candidates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    -induced stress echocardiography appears to be more sensitive than other non-invasive tests, including vasodilator-induced stress nuclear scintigraphy. In one study of 125 candidates (39 percent diabetic patients), all patients underwent coronary angiography, dobutamine stress echocardiography, and resting and exercise electrocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/33\">",
"     33",
"    </a>",
"    ]. Independent predictors of severe coronary artery disease (defined as luminal stenosis &gt;70 percent by visual estimation in at least one epicardial artery) were a positive stress echo result (odds ratio of 23, 95% CI 6-88) or an abnormal resting electrocardiogram (odds ratio 7, 95% CI 2-34). Overall, the sensitivity and specificity of dobutamine stress echocardiography was approximately 75 percent.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    -induced stress echocardiography may also be used to stratify cardiovascular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. This was assessed in a meta-analysis that evaluated the prognostic value of dobutamine stress echocardiography (four trials) and thallium scintigraphy (four studies with pharmacologic stress and four with exercise stress) in dialysis patients undergoing assessment for kidney or kidney-pancreas transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/34\">",
"     34",
"    </a>",
"    ]. Overall, positive tests, compared with negative tests, resulted in a significantly increased risk of myocardial infarction (RR of 2.73, 95% CI 1.25-5.97) and coronary death (RR of 2.92, 95% CI 1.66-5.12). Among diabetic patients, subgroup analyses found that positive tests were also associated with a higher risk of coronary death (RR of 3.95, 95% CI 1.48-10.5) and myocardial infarction (RR of 2.68, 95% CI 0.95-7.57). Both reversible and fixed detects were associated with poor prognosis in diabetic patients with ESRD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1393888242\">",
"    <span class=\"h3\">",
"     Intervention following positive screening test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implicit in the rationale for screening is that intervention will improve outcomes. The optimal intervention for diabetic transplant candidates who have asymptomatic coronary heart disease is not known. In one study, published in 1992, 151 consecutive asymptomatic type 1 diabetic patients were screened prior to transplantation with cardiac catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/36\">",
"     36",
"    </a>",
"    ]. Significant disease as defined by stenosis &gt;75 percent in one or more coronary arteries was identified in 31 patients, of which 26 agreed to be randomized to either medical therapy (calcium channel blocker plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) or intervention (angioplasty or bypass). Ten of 13 medically managed patients had an adverse coronary event versus 2 out of 13 revascularized patients in a median follow up of 8.4 months. In addition, 4 out of 13 medically managed patients died of myocardial infarction during the two-year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/36\">",
"     36",
"    </a>",
"    ]. However this study has never been validated in a larger prospective study with long-term follow-up. Randomized trials are needed to determine the optimal therapeutic approach to asymptomatic transplant candidates with coronary heart disease.",
"   </p>",
"   <p>",
"    Issues related to reevaluation among diabetic patients on the waitlist for a kidney transplant are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11240?source=see_link\">",
"     \"The kidney transplant waiting list\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Evaluation of peripheral vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;To identify patients with iliac calcifications, we screen all diabetic patients older than 45 years of age, or those with poor femoral pulses or evidence of vascular disease elsewhere (eg, coronary heart disease or cerebrovascular disease), with a noncontrast abdominopelvic CT scan. Peripheral vascular disease is common among diabetic patients with ESRD and may prevent a successful anastomosis to the kidney allograft. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20905?source=see_link&amp;anchor=H2#H2\">",
"     \"Peripheral artery disease in chronic kidney disease\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is difficult to establish in such patients because of the presence of medial artery calcifications that render vessels non compressible for a standard ankle brachial index and or toe brachial index. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20905?source=see_link&amp;anchor=H7#H7\">",
"     \"Peripheral artery disease in chronic kidney disease\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with symptoms of peripheral vascular disease (eg, claudication) are referred to a vascular specialist for further assessment and testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     POSTTRANSPLANTION CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many complications related to kidney transplantation may occur in all transplant recipients. These include allograft rejection and an increased risk of infection and malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a focused discussion on some of these issues as they related to the diabetic patient with a kidney transplant.",
"   </p>",
"   <p>",
"    Additional issues that may affect all diabetic patients, such as gastroparesis, autonomic neuropathy, peripheral neuropathy, and foot ulcers, are presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22347785\">",
"    <span class=\"h2\">",
"     Allograft rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of rejection in diabetics has not been well-studied. In small studies, the risk of acute rejection was found to be similar between diabetic and nondiabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. This issue in all kidney transplant recipients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=see_link\">",
"     \"Acute renal allograft rejection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22347792\">",
"    <span class=\"h2\">",
"     Malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a paucity of data exists, the incidence of malignancies appears to be similar in kidney transplant recipients with and without diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/39\">",
"     39",
"    </a>",
"    ]. However, one study reported a greater incidence of malignancies in patients who receive simultaneous pancreas-kidney transplant compared with kidney transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/40\">",
"     40",
"    </a>",
"    ]. It is unclear whether this may have been secondary to differences in the intensity of immunosuppression among such patients.",
"   </p>",
"   <p>",
"    This issue in all kidney transplant recipients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22347799\">",
"    <span class=\"h2\">",
"     Viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues surrounding viral infection and diabetes post-transplant are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26250?source=see_link\">",
"     \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the widespread use of prophylactic antibiotics, urinary tract infections (UTIs) remain common post-transplantation among kidney transplant recipients.",
"   </p>",
"   <p>",
"    Post-transplant UTIs are more common in diabetic versus nondiabetic transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. This is in part due to the high incidence of neurogenic bladders among diabetic patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20579?source=see_link\">",
"     \"Urinary tract infection in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach to prophylactic therapy among diabetic recipients is the same as that for nondiabetic recipients. Among diabetic and nondiabetic recipients, we recommend the administration of an antibiotic agent for prophylaxis therapy against UTIs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20579?source=see_link\">",
"     \"Urinary tract infection in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recurrent diabetic nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the vast majority of diabetic transplant recipients have developed histological changes of recurrent diabetic nephropathy, in some cases within one year post-transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/43\">",
"     43",
"    </a>",
"    ]. However, the incidence of diabetic nephropathy as a cause of graft failure is thought to be rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/44\">",
"     44",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    Recurrent disease in the allograft can theoretically be prevented by optimal glycemic control. A single randomized trial of type 1 diabetic patients showed that, compared with standard therapy, intensive insulin therapy at the time of transplantation was associated with fewer pathological changes of diabetic nephropathy on five-year kidney allograft biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/39/36472/abstract/45\">",
"     45",
"    </a>",
"    ]. Recurrent diabetic nephropathy is prevented by a successful kidney pancreas transplant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/19/41272?source=see_link&amp;anchor=H18272152#H18272152\">",
"     \"Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus\", section on 'Diabetic nephropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycemic control may become acutely worse in the immediate post-transplant period, in part due to increased insulin resistance and impaired insulin secretion associated with steroids and other immunosuppressant medications. Issues surrounding glycemic control among post-transplant diabetics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26250?source=see_link\">",
"     \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in Western societies. Diabetic nephropathy is the etiology of ESRD in approximately 23 percent of kidney transplant recipients transplanted in the United States. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kidney transplantation is generally the optimal renal replacement therapy for diabetic patients with ESRD. Among all diabetic patients with ESRD who are eligible for transplantation, we recommend a kidney transplant rather than dialysis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1212465755\">",
"       'Transplantation versus dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The timing of transplantation influences patient survival; patients who undergo transplantation without ever starting dialysis have decreased mortality compared with those who are dialyzed prior to transplantation. Among predialysis diabetic patients with chronic kidney disease who are eligible for transplantation, we recommend whenever possible preemptive kidney transplantation rather than initiation of dialysis followed by transplantation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Living donor kidneys are preferred to deceased donor kidneys. (See",
"      <a class=\"local\" href=\"#H1212465762\">",
"       'Preemptive transplantation and living donor versus deceased kidneys'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The wait time for an expanded criteria donor (ECD) kidney may be less than that for a standard donor kidneys. Diabetic patients who receive expanded criteria donor (ECD) kidneys appear to be likely to live longer than if they remained on dialysis, although the ECD kidney may not be of the same quality as a standard donor kidney. We suggest that all wait-listed diabetic patients register on both the standard-donor wait list and the ECD wait list (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1212466317\">",
"       'Expanded criteria kidneys'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the goal of preemptive transplantation, diabetics should be referred to a transplant center when the glomerular filtration rate is less than 30",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Timing of referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To help detect coronary heart disease and perhaps lower the risk of adverse effects with transplantation, diabetic patients with ESRD are evaluated for the presence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      absence of coronary heart disease. The optimal approach is unclear. We suggest the following approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H2217195\">",
"       'Approach to evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All diabetic transplant candidates are evaluated with a history, physical examination, electrocardiogram, and chest radiograph.",
"     </li>",
"     <li>",
"      Diabetic patients who have symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs consistent with coronary heart disease or a history of myocardial infarction undergo cardiac catheterization unless they recently underwent successful revascularization.",
"     </li>",
"     <li>",
"      Diabetic patients who do not undergo initial screening coronary angiography have a screening",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiography. If positive, the decision to proceed with angiography and possible angioplasty or surgery is usually made in conjunction with the patients' cardiologist. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cardiac evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.unos.org (Accessed on June 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/2\">",
"      Gaston RS, Basadonna G, Cosio FG, et al. Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. Am J Kidney Dis 2004; 44:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/3\">",
"      Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998; 9:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/4\">",
"      Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/5\">",
"      Ojo AO, Port FK, Wolfe RA, et al. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis 1994; 24:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/6\">",
"      Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/7\">",
"      Rabbat CG, Thorpe KE, Russell JD, Churchill DN. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000; 11:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/8\">",
"      Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 2001; 12:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/9\">",
"      Oniscu GC, Brown H, Forsythe JL. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol 2005; 16:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/10\">",
"      Gill JS, Tonelli M, Johnson N, et al. The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation. Kidney Int 2005; 68:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/11\">",
"      Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/12\">",
"      Lentine KL, Schnitzler MA, Abbott KC, et al. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis 2005; 46:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/13\">",
"      Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/14\">",
"      Lentine KL, Rocca Rey LA, Kolli S, et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol 2008; 3:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/15\">",
"      Cosio FG, Hickson LJ, Griffin MD, et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant 2008; 8:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/16\">",
"      Kasiske BL, Snyder JJ, Matas AJ, et al. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 2002; 13:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/17\">",
"      Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/18\">",
"      Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001; 344:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/19\">",
"      Gill JS, Tonelli M, Johnson N, Pereira BJ. Why do preemptive kidney transplant recipients have an allograft survival advantage? Transplantation 2004; 78:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/20\">",
"      Becker BN, Rush SH, Dykstra DM, et al. Preemptive transplantation for patients with diabetes-related kidney disease. Arch Intern Med 2006; 166:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/21\">",
"      Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005; 294:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/22\">",
"      Schold JD, Meier-Kriesche HU. Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis? Clin J Am Soc Nephrol 2006; 1:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/23\">",
"      Snoeijs MG, Schaubel DE, Hen&eacute; R, et al. Kidneys from donors after cardiac death provide survival benefit. J Am Soc Nephrol 2010; 21:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/24\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/25\">",
"      Witczak BJ, Hartmann A, Jenssen T, et al. Routine coronary angiography in diabetic nephropathy patients before transplantation. Am J Transplant 2006; 6:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/26\">",
"      Ramanathan V, Goral S, Tanriover B, et al. Screening asymptomatic diabetic patients for coronary artery disease prior to renal transplantation. Transplantation 2005; 79:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/27\">",
"      Manske CL, Thomas W, Wang Y, Wilson RF. Screening diabetic transplant candidates for coronary artery disease: identification of a low risk subgroup. Kidney Int 1993; 44:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/28\">",
"      Ma IW, Valantine HA, Shibata A, et al. Validation of a screening protocol for identifying low-risk candidates with type 1 diabetes mellitus for kidney with or without pancreas transplantation. Clin Transplant 2006; 20:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/29\">",
"      Scandling JD. Kidney transplant candidate evaluation. Semin Dial 2005; 18:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/30\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/31\">",
"      Elsner D. How to diagnose and treat coronary artery disease in the uraemic patient: an update. Nephrol Dial Transplant 2001; 16:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/32\">",
"      Schmidt A, Stefenelli T, Schuster E, Mayer G. Informational contribution of noninvasive screening tests for coronary artery disease in patients on chronic renal replacement therapy. Am J Kidney Dis 2001; 37:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/33\">",
"      Sharma R, Pellerin D, Gaze DC, et al. Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renal transplant candidates. Nephrol Dial Transplant 2005; 20:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/34\">",
"      Rabbat CG, Treleaven DJ, Russell JD, et al. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. J Am Soc Nephrol 2003; 14:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/35\">",
"      De Vriese AS, De Bacquer DA, Verbeke FH, et al. Comparison of the prognostic value of dipyridamole and dobutamine myocardial perfusion scintigraphy in hemodialysis patients. Kidney Int 2009; 76:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/36\">",
"      Manske CL, Wang Y, Rector T, et al. Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992; 340:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/37\">",
"      Schiel R, Heinrich S, Steiner T, et al. Post-transplant diabetes mellitus: risk factors, frequency of transplant rejections, and long-term prognosis. Clin Exp Nephrol 2005; 9:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/38\">",
"      Schiel R, Heinrich S, Steiner T, et al. Long-term prognosis of patients after kidney transplantation: a comparison of those with or without diabetes mellitus. Nephrol Dial Transplant 2005; 20:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/39\">",
"      Bastos M, Baptista C, Campos MV, et al. Kidney transplantation and diabetes: posttransplantation malignancy. Transplant Proc 2003; 35:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/40\">",
"      Martinenghi S, Dell'Antonio G, Secchi A, et al. Cancer arising after pancreas and/or kidney transplantation in a series of 99 diabetic patients. Diabetes Care 1997; 20:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/41\">",
"      Valera B, Gentil MA, Cabello V, et al. Epidemiology of urinary infections in renal transplant recipients. Transplant Proc 2006; 38:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/42\">",
"      Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant 2006; 20:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/43\">",
"      Owda AK, Abdallah AH, Haleem A, et al. De novo diabetes mellitus in kidney allografts: nodular sclerosis and diffuse glomerulosclerosis leading to graft failure. Nephrol Dial Transplant 1999; 14:2004.",
"     </a>",
"    </li>",
"    <li>",
"     Siddqi, N, Hariharan, S, Danovitch, G. Evaluation and Preparation of Renal Transplant Candidates. Handbook of Kidney Transplantation, Fourth Ed., Lippincott Williams &amp; Wilkins, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/39/36472/abstract/45\">",
"      Barbosa J, Steffes MW, Sutherland DE, et al. Effect of glycemic control on early diabetic renal lesions. A 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients. JAMA 1994; 272:600.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7349 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36472=[""].join("\n");
var outline_f35_39_36472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENEFITS OF TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1212465755\">",
"      Transplantation versus dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1212465762\">",
"      Preemptive transplantation and living donor versus deceased kidneys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1212466317\">",
"      Expanded criteria kidneys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRETRANSPLANT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Timing of referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cardiac evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H617455917\">",
"      - Prevalence of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2217195\">",
"      - Approach to evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1393888242\">",
"      - Intervention following positive screening test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Evaluation of peripheral vascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      POSTTRANSPLANTION CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22347785\">",
"      Allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22347792\">",
"      Malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22347799\">",
"      Viral infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recurrent diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=related_link\">",
"      Acute renal allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/19/41272?source=related_link\">",
"      Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33559?source=related_link\">",
"      Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11224?source=related_link\">",
"      Dialysis issues prior to and after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26250?source=related_link\">",
"      New onset diabetes after transplant (NODAT) in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/16/7434?source=related_link\">",
"      Patient selection for and immunologic issues relating to kidney-pancreas transplantation in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20905?source=related_link\">",
"      Peripheral artery disease in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11240?source=related_link\">",
"      The kidney transplant waiting list",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20579?source=related_link\">",
"      Urinary tract infection in renal transplant recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_39_36473="Darunavir: Drug information";
var content_f35_39_36473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Darunavir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/26/33189?source=see_link\">",
"    see \"Darunavir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3020778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prezista&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7828263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Prezista&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3020782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Protease Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3020819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Treatment of HIV infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Therapy-naive:",
"     </b>",
"     800 mg once daily; coadministration with ritonavir 100 mg once daily is required.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended (with ritonavir) as a first-line therapy with tenofovir/emtricitabine in antiretroviral na&iuml;ve patients (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Therapy-experienced:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Genotypic testing is recommended in therapy experienced patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      With no darunavir resistance-associated substitutions:",
"     </i>",
"     800 mg once daily; coadministration with ritonavir 100 mg once daily is required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      With &ge;1 darunavir resistance-associated substitution:",
"     </i>",
"     600 mg twice daily; coadministration with ritonavir 100 mg twice daily is required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      If genotypic testing is not possible:",
"     </i>",
"     600 mg twice daily, coadministered with ritonavir 100 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6892744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Treatment of HIV infection:",
"     </b>",
"     Children &ge;3 years and Adolescents: Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Coadministration with ritonavir is required; do not exceed the maximum recommended darunavir adult dose (800 mg to 1200 mg daily depending upon indication). Genotypic testing is recommended in therapy-experienced patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment-naive patients or treatment-experienced with no darunavir resistance-associated substitutions:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosing recommendations based on body weight using the oral suspension:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;10 kg to &lt;11 kg: 350 mg once daily with ritonavir 64 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;11 kg to &lt;12 kg: 385 mg once daily with ritonavir 64 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;12 kg to &lt;13 kg: 420 mg once daily with ritonavir 80 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;13 kg to &lt;14 kg: 455 mg once daily with ritonavir 80 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;14 kg to &lt;15 kg: 490 mg once daily with ritonavir 96 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosing recommendations based on body weight using the oral solution or tablets:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;15 kg to &lt;30 kg: 600 mg once daily with ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;30 kg to &lt;40 kg: 675 mg once daily with ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;40 kg: 800 mg once daily with ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment-experienced patients with at &ge;1 darunavir resistance-associated substitution:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosing recommendations based on body weight using the oral suspension:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;10 kg to &lt;11 kg: 200 mg twice daily with ritonavir 32 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;11 kg to &lt;12 kg: 220 mg twice daily with ritonavir 32 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;12 kg to &lt;13 kg: 240 mg twice daily with ritonavir 40 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;13 kg to &lt;14 kg: 260 mg twice daily with ritonavir 40 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;14 kg to &lt;15 kg: 280 mg twice daily with ritonavir 48 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosing recommendations based on body weight using the oral solution or tablets:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;15 kg to &lt;30 kg: 375 mg twice daily with ritonavir 48 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;30 kg to &lt;40 kg: 450 mg twice daily with ritonavir 60 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;40 kg: 600 mg twice daily with ritonavir 100 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3020820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment provided in manufacturer's labeling; however, need for adjustment not expected based on pharmacokinetic data.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3020821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Use not recommended (contraindicated in Canadian labeling).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F6788823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe rash: Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     New or worsening liver dysfunction: Consider interrupting or discontinuing treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3020832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prezista&reg;: 75 mg, 150 mg, 400 mg, 600 mg, 800 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3020780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F13660602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prezista&reg; 100 mg/mL oral suspension: FDA approved December 2011; availability expected in the second quarter of 2012",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3020823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Coadministration with ritonavir and food is required (bioavailability is increased). Shake suspension prior to each dose; use provided oral dosing syringe to measure dose.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3020785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of HIV-1 infections in combination with ritonavir and other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3020796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     As a class, protease inhibitors potentially cause dyslipidemias which includes elevated cholesterol and triglycerides and a redistribution of body fat centrally to cause increased abdominal girth, buffalo hump, facial atrophy, and breast enlargement. These agents also cause hyperglycemia. Frequency of adverse events is reported for darunavir/ritonavir. See also Ritonavir monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (children: grade 3: 1%; adults: grade 2: 16% to 25%; grade 3: 1% to 10%), LDL increased (children: grade 3: 3%; adults: grade 2: 14%; grade 3: 5% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (children: 13% to 33%; adults 2% to 5%), nausea (4% to 25%), diarrhea (children: 11% to 19%; adults: 8% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system:  Headache (children: 9%; adults: 3% to 6%), fatigue (children: 3%; adults: &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (children: 5% to 10%; adults: 6% to 7%), pruritus (children: 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (grade 2: 7% to 10%; grade 3: &le;1%; grade 4: &lt;1%), triglycerides increased (grade 2: 3% to 10%; grade 3: 1% to 7%; grade 4: &le;3%), diabetes mellitus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (children: 8% to 10%; adults: 5% to 6%), amylase increased (children: grade 3: 4%, grade 4: 1%; adults: grade 2: 5% to 6%, grade 3: 3% to 7%), appetite decreased (children: 8%), lipase increased (children: grade 3: 1%; adults: grade 2: 2% to 3%, grade 3; &le;2%; grade 4: &lt;1%), abdominal distention (2%), anorexia (2%), dyspepsia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (children: grade 3: 3%; grade 4: 1%; adults: grade 2: 7%, grade 3: 2% to 3%; grade 4: &le;1%), AST increased (children: grade 3: 1%; adults: grade 2: 6%; grade 3: 2% to 4%; grade 4: &lt;1%), alkaline phosphatase (grade 2: &le;2%; grade 3: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Acute renal failure, acute respiratory distress syndrome, allergic dermatitis, alopecia, anemia, angioedema, bile duct obstruction, bradycardia, cerebrovascular accident, dermatitis medicamentosa, erythema multiforme, exanthematous pustulosis (acute, generalized), fat redistribution (eg, buffalo hump, increased abdominal girth, breast engorgement, facial atrophy), folliculitis, gynecomastia, hematuria, hepatic cirrhosis, hepatic failure, hepatic neoplasm (malignant), hepatitis (acute and cytolytic), hepatotoxicity, hyperbilirubinemia, hyperkalemia, hyperlipidemia, hypersensitivity, hypertension, hyperthermia, immune reconstitution syndrome, infection (including clostridium, cryptosporidiosis, cytomegalovirus encephalitis, hepatitis B, esophageal candidiasis), large B-cell neoplasm (diffuse), lipoatrophy, lymphoma, maculopapular rash, metabolic acidosis, MI, myocarditis, nephrolithiasis, neuromyopathy, obesity, osteonecrosis, osteopenia, osteoporosis, pancreatitis, pancytopenia, peripheral neuropathy, pharyngeal lesion, pneumothorax, progressive multifocal leukoencephalopathy, rectal hemorrhage, renal insufficiency, renal tubular necrosis, rhabdomyolysis (coadministration with HMG-CoA reductase inhibitors), respiratory failure, seizures, sepsis, Stevens-Johnson syndrome, suicide (completed), tachycardia, toxic skin eruption, toxic epidermal necrolysis, transient ischemic attack",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3020791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Coadministration with medications highly dependent upon CYP3A4 for clearance and for which increased levels are associated with serious and/or life-threatening events (includes alfuzosin, cisapride, ergot alkaloids [eg, dihydroergotamine, ergonovine, ergotamine, methylergonovine], lovastatin, midazolam [oral], pimozide, rifampin, sildenafil (when used for pulmonary artery hypertension [eg, Revatio&reg;]), simvastatin, St John's wort, triazolam",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications: Hypersensitivity to darunavir or any component of the formulation; coadministration with amiodarone, lidocaine (systemic), quinidine; severe (Child-Pugh class C) hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3020792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Infrequent cases of drug-induced hepatitis (including acute and cytolytic) have been reported. Liver injury has been reported with use (including some fatalities), though generally in patients on multiple medications, with advanced HIV disease, hepatitis B/C coinfection, and/or immune reconstitution syndrome. Monitor patients closely; consider interrupting or discontinuing therapy if signs/symptoms of liver impairment occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Protease inhibitors have been associated with a variety of hypersensitivity events (some severe), including rash, anaphylaxis (rare), angioedema, bronchospasm, erythema multiforme, Stevens-Johnson syndrome (rare), acute generalized exanthematous pustulosis, and/or toxic epidermal necrolysis. Discontinue treatment if severe skin reactions develop. Severe skin reactions may be accompanied by fever, malaise, fatigue, arthralgias, hepatitis, oral lesions, blisters, conjunctivitis, and/or eosinophilia. Mild-to-moderate rash may occur early in treatment and resolve with continued therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased cholesterol: Increases in total cholesterol and triglycerides have been reported; screening should be done prior to therapy and periodically throughout treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Pancreatitis has been observed during therapy; use caution in patients at risk for pancreatitis including those with elevated triglycerides, advanced HIV disease, or history of pancreatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Use with caution in patients with sulfonamide allergy (contains sulfa moiety).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Changes in glucose tolerance, hyperglycemia, exacerbation of diabetes, DKA, and new-onset diabetes mellitus have been reported in patients receiving protease inhibitors. Initiation or dose adjustments of antidiabetic agents may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemophilia A or B: Use with caution in patients with hemophilia A or B; increased bleeding during protease inhibitor therapy has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: May exacerbate pre-existing hepatic dysfunction; use with caution in patients with underlying hepatic disease, such as hepatitis B or C or cirrhosis. Use is not recommended in severe impairment. Use in severe impairment is contraindicated in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F3020803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3020802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg/day or every other day in adult patients taking darunavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting darunavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Darunavir may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: Darunavir may increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Darunavir may decrease the serum concentration of Didanosine. More specifically, this interaction is likely due to the effects of food (with which darunavir/ritonavir are taken) on didanosine, which is supposed to be given on an empty stomach.  Management: Didanosine should be administered 1 hour prior to or 2 hours after administration of darunavir/ritonavir (which must be taken with food).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: Darunavir may increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir, saquinavir, and lopinavir (with low-dose ritonavir). Management: Low-dose ritonavir boosting must be used when any protease inhibitor is used with etravirine.  Avoid use of etravirine in combination with atazanavir, fosamprenavir, full-dose ritonavir (600 mg twice daily), or tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Darunavir may increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Darunavir.  Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving darunavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Darunavir may increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Darunavir.  Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving darunavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Darunavir may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Darunavir may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of lopinavir",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Protease Inhibitors may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norethindrone: Darunavir may decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: Darunavir may decrease the serum concentration of PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Darunavir may increase the serum concentration of Pravastatin. This effect has only been demonstrated with darunavir/ritonavir. The individual contributions of darunavir and ritonavir are unknown.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Darunavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Darunavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Darunavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Darunavir may increase the serum concentration of Rilpivirine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sertraline: Darunavir may decrease the serum concentration of Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Darunavir may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Darunavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with darunavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Darunavir may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Darunavir may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3020806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Absorption and bioavailability are increased when administered with food. Management: Take with meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John&rsquo;s wort may decrease the plasma levels of darunavir. Garlic may decrease the serum concentration of darunavir. Management: Taking St John's wort concomitantly with darunavir is contraindicated. Use of garlic supplements with darunavir is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3020786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3020787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. Darunavir crosses the placenta. Safety and pharmacokinetic data are limited in pregnancy. Serum concentrations may be low with once-daily dosing; therefore, some experts recommend twice-daily dosing during pregnancy (studies are ongoing). The DHHS Perinatal HIV Guidelines consider darunavir to be an alternative protease inhibitor (PI) when combined with low-dose ritonavir boosting. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and PIs should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3020789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3020790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3020822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Absorption increased with food. Take with meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6133126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Prezista Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (200 mL): $727.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Prezista Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (480): $1308.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (240): $1308.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (60): $1308.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (60): $1308.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mg (30): $1308.94",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3020825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Viral load, CD4, serum glucose; transaminase levels prior to and during therapy (increase monitoring in patients at risk for liver impairment), cholesterol, triglycerides",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Prezista (AR, AT, AU, BB, BE, BM, BS, BZ, CH, CL, CN, CO, CZ, DE, DK, DO, EE, FR, GB, GR, GY, HK, HN, IE, IL, IT, JM, KP, MY, NL, NO, NZ, PL, PR, PT, RU, SE, SG, SR, TH, TT, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3020809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Binds to the site of HIV-1 protease activity and inhibits cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3020811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     All kinetic parameters derived in the presence of ritonavir coadministration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Increased 30% with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~95%; primarily to alpha",
"     <sub>",
"      1",
"     </sub>",
"     acid glycoprotein (AAG)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP3A4 to minimally-active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 82%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 2.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~80%, 41% as unchanged drug); urine (~14%, 8% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, Department of Health and Human Services,&rdquo; August 11, 2011. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8842 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36473=[""].join("\n");
var outline_f35_39_36473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020778\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7828263\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020782\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020819\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892744\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062962\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020820\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020821\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6788823\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020832\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020780\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13660602\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020823\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020785\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020796\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020791\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020792\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020803\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020802\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020806\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020786\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020787\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020789\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020790\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020822\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6133126\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020825\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539977\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020809\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3020811\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8842\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8842|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/26/33189?source=related_link\">",
"      Darunavir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_39_36474="Acanthosis nigricans neck";
var content_f35_39_36474=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64585%7EDERM%2F66384%7EDERM%2F81693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64585%7EDERM%2F66384%7EDERM%2F81693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acanthosis nigricans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Velvety, hyperpigmented plaques are present on the neck of this patient with acanthosis nigricans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acanthosis nigricans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmented velvety plaques are present in the axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acanthosis nigricans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Close view of acanthosis nigricans on the posterior neck. Hyperpigmented velvety plaques are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36474=[""].join("\n");
var outline_f35_39_36474=null;
var title_f35_39_36475="Giant cell v Takayasu arteritis";
var content_f35_39_36475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distinguishing features of giant cell versus Takayasu arteritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Finding",
"      </td>",
"      <td class=\"subtitle1\">",
"       Giant cell arteritis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Takayasu arteritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Female-to-male ratio",
"      </td>",
"      <td>",
"       3:2",
"      </td>",
"      <td>",
"       7:1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age at onset",
"      </td>",
"      <td>",
"       &gt;50 years",
"      </td>",
"      <td>",
"       &lt;40 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ethnic ancestry",
"      </td>",
"      <td>",
"       European",
"      </td>",
"      <td>",
"       Asian",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Histopathology",
"      </td>",
"      <td>",
"       Granulomatous inflammation",
"      </td>",
"      <td>",
"       Granulomatous inflammation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Primary vessels involved",
"      </td>",
"      <td>",
"       External carotid artery branches",
"      </td>",
"      <td>",
"       Aorta and branches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Renovascular hypertension",
"      </td>",
"      <td>",
"       Rare",
"      </td>",
"      <td>",
"       Common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HLA association",
"      </td>",
"      <td>",
"       HLA-DR4",
"      </td>",
"      <td>",
"       HLA-Bw52",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Course",
"      </td>",
"      <td>",
"       Self-limited",
"      </td>",
"      <td>",
"       Chronic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Response to corticosteroids",
"      </td>",
"      <td>",
"       Excellent",
"      </td>",
"      <td>",
"       Excellent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Surgical intervention needed",
"      </td>",
"      <td>",
"       Rare",
"      </td>",
"      <td>",
"       Common",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Michel, BA, Arend, WP, Hunder, GG. Clinical differentiation between giant cell (temporal) arteritis and Takayasu's arteritis. J Rheumatol 1996; 23:106.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36475=[""].join("\n");
var outline_f35_39_36475=null;
var title_f35_39_36476="Comorbidities and medications affecting severity and treatment";
var content_f35_39_36476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comorbidities and concurrent medications that might impact the severity and treatment of anaphylaxis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Comorbidities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other pulmonary diseases (eg, COPD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular diseases (eg, ischemic heart disease, hypertensive vascular disease, cardiomyopathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mastocytosis and clonal mast cell disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent intracranial surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthyroidism (untreated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Concurrently administered medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &beta;-adrenergic blockers*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &alpha;-adrenergic blockers",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiotensin-converting enzyme inhibitors",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiotensin II receptor blockers",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monoamine oxidase inhibitors",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ADHD medications",
"        <sup>",
"         &yen;",
"        </sup>",
"        (eg, stimulants such as methylphenidate and amphetamines)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recreational use of cocaine",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     COPD: chronic obstructive pulmonary disease; ADHD: attention deficit-hyperactivity disorder.",
"     <br>",
"      * Beta-adrenergic blockers, administered orally or topically (eg, eye drops) may be associated with severe anaphylaxis and may also make anaphylaxis more difficult to treat by causing unopposed alpha-adrenergic effects, hypertension, and reduced bronchodilator response to the beta-adrenergic effects of endogenous or exogenous epinephrine.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Alpha-adrenergic blockers may decrease the effects of endogenous or exogenous epinephrine at alpha-adrenergic receptors, potentially making patients less response to the alpha-adrenergic effects of epinephrine.",
"       <br>",
"        &Delta; Potential interference with endogenous compensatory responses.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Potential increase in adverse effects of epinephrine because of prevention of epinephrine uptake at adrenergic receptors.",
"         <br>",
"          &sect; Potentiate epinephrine's effects by inhibiting its metabolism by monoamine oxidase.",
"          <br>",
"           &yen; Side effects are similar to those of epinephrine.",
"           <br>",
"            Potentiates epinephrine's effects, especially cardiovascular effects, by preventing its re-uptake into adrenergic neurons.",
"            <br>",
"             <br/>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Simons FER. Anaphylaxis, killer allergy: Long-term management in the community. J Allergy Clin Immunol 2006; 117:367. Copyright &copy; 2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36476=[""].join("\n");
var outline_f35_39_36476=null;
var title_f35_39_36477="Medications associated with easy bruising";
var content_f35_39_36477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications associated with easy bruising",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Antibiotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Most broad spectrum antibiotics, especially with long-term use",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Anticoagulants*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Heparin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Warfarin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Low molecular weight heparins (enoxaparin, dalteparin, tinzaparin, nadroparin)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Argatroban",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dabigatran",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fondaparinux",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lepirudin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fluoxetine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sertraline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Paroxetine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Antiinflammatories (NSAIDS)*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Celecoxib",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diclofenac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diflusinal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fenoprofen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Flurbiprofen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ibuprofen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Indomethacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ketorolac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mefenamic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Meloxicam",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nabumetone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Naproxen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Oxaprozin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Piroxicam",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Salsalate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sulindac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Antineoplastics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Multiple agents, primarily manifesting via decreased platelet production",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Antiplatelet medications*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Abcixamab",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Aspirin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cilostazol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Clopidogrel",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dipyridamole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Epdifibatide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Prasugrel",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tirofiban",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Corticosteroids*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dexamethasone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Prednisone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hydrocortisone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fluticasone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Triamcinolone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Quinidine",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Herbs and supplements",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dark chocolate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fish oil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Garlic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ginger",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gingko",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vitamin E",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wood ear mushroom",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alcohol",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Frequently seen causes.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36477=[""].join("\n");
var outline_f35_39_36477=null;
var title_f35_39_36478="Evaluation suspected SAH";
var content_f35_39_36478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F74767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F74767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Evaluation of suspected subarachnoid hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 435px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SAH: subarachnoid hemorrhage.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36478=[""].join("\n");
var outline_f35_39_36478=null;
var title_f35_39_36479="Survival for all patients";
var content_f35_39_36479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F87270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F87270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Survival following surgery for pleural mesothelioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 276px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Staging was based upon most accurate available clinical and/or pathologic data.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rusch VW, Giroux D, Kennedy C, et al. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database. J Thorac Oncol 2012; 7:1631. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_39_36479=[""].join("\n");
var outline_f35_39_36479=null;
